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SERUM LEPTIN LEVEL AND ITS ASSOCIATION WITH            
BLOOD PRESSURE, BODY MASS INDEX, WAIST HIP RATIO        
AND  WAIST HEIGHT RATIO 
Abstract: 
Background: Leptin is a product of Ob gene secreted from adipose tissue. It is 
a key neuroendocrine hormone regulating food intake, metabolism, and fat 
accumulation, and it may also affect blood pressure and contribute to 
hypertension through sympathetic activation in the vasculature or at the renal 
level. Hyperleptinemia also seen in obesity, which is a major comorbid  
condition  of  hypertension. Aim : To study the relationship between serum 
leptin level and Blood pressure in association with Age, Gender, Body mass 
index, Waist hip ratio and Waist height ratio. Materials and methods: Study 
group : 48 hypertensive patients ( 26 males, 22 females) in the age group of   
35-75 years. Control group include 42 normotensive persons (22 males, 20 
females) in the same age group. After recording the history, clinical 
examination and blood pressure, weight (in Kg), height (in cms) waist 
circumference (in cms) and hip circumference (in cms) were measured. BMI, 
waist hip ratio and waist height ratio were calculated. Blood sample was 
collected under strict aseptic precaution after overnight fasting and then 
centrifuged to collect the serum. Serum leptin level was estimated by using 
KAP 2281 Human leptin ELISA kit. The values were statistically analyzed by 
chi square tests and student ‘t’ test. Result : In the present study, serum leptin 
level was significantly increased with the p value of < 0.0001 in hypertensive 
patients (8.15 ± 2.68) when compared to normotensive persons (1.74 ± 1.04). 
And also it was found that serum leptin level positively correlated with systolic 
blood pressure (P < 0.0268), age (P< 0. 0001), BMI  (P <0.0467), waist hip ratio 
(P<0.0001) and waist height ratio (P <0.0001). Conclusion: From this study it 
was concluded that, there is a strong positive correlation between serum leptin 
level and high blood pressure, age, body mass index, waist hip ratio and waist 
height ratio. 
Key words: leptin, blood pressure, body mass index, waist hip ratio, waist 
height ratio. 
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INTRODUCTION 
“Healthy  citizens  are  the  greatest  asset  any  country  can  have”  -  A  
popular  Quote  by  Winston  Churchill  explains  the  importance  of  
health.  But   health  is  not  merely  an  absence  of  disease.  Nowadays  
we  live  in  a  rapidly  changing  environment  and  the  human  health  is 
constantly  challenged  by  factors  like  Demographic  aging, 
Urbanization,  and  Globalization  of  unhealthy  lifestyles.  They  
contribute  to  sharp  rise  in  prevalence  of  chronic  diseases  like  
hypertension,  diabetes  mellitus,  cardiovascular  diseases,  cancer  etc.  
These  pathologies  constitute  a  heavy  social  and  economic  burden  
because  they  directly  contribute  to  the  loss  of   DALY  ( Disability   
adjusted  life  years )  for  citizens  and   represent  considerable  
healthcare  expenditure  for  society.  With  longer  life  expectancy  we  
need  to  improve  our  quality  of  life  also.  
Hypertension,  one  among  the   chronic  diseases  also  called  a  silent  
killer  has  more  impact  on  acute  social  and  economic  effects  on  
population.  Affecting  1  billion  people  worldwide,  Hypertension  
remains  the  most common,  readily  identifiable,  treatable  and  
preventable  risk  factor  for  Heart  disease  and  stroke.  Currently  high  
blood  pressure  causes  about  54%  of   stroke,  47%   of   Ischemic  
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Heart  Disease  worldwide1.  There  is  continuous  relationship  between  
blood  pressure  and   its  complications  from  values  as  low  as  115/75  
mm Hg.  The relationship  is  steeper  for  stroke  than  for  Coronary  
artery  disease.  The  mortality  doubles  with  every  20/10  mm Hg  rise  
in   blood  pressure2.   
Thus  high  blood  pressure  remains  the  number  one  attributable  risk  
factor   for  death  throughout   the  world3.  Its  global  burden  is  rising  
and  projected  to  affect  1.5  billion  people  -   1/3  of  world’s  
population  by  the  year  2025.  Nearly  half  of  this  burden  is  with  
hypertensives  and   half  lies  in  prehypertensives1.  
So  hypertension  becomes  one  of  the  world’s  greatest  public  health  
problems.  Inherent  variability  in  blood  pressure  and  asymptomatic  
nature  of  the  disease  can  delay  diagnosis  and  treatment4.  So  it  
demands  to  establish  simple  and  better   diagnostic  tools  to  detect  
the  condition  well  before   the   rise  in  blood  pressure. 
The  etiology  of  hypertension   is  multifactorial.  The  most   important  
predictors  are  behavioural  determinants  like  dietary  consumption  of  
calories  and  salt,  stress,  lack  of  physical  activity4.  Among  them,  
obesity  gains  more  importance  because  of  changing  lifestyle  and  
3 
 
sedentary  habits.  It  has  become  a  growing  epidemic,  the  world  is  
facing  today.   
Not  to  be   surprised  that  most  of  the  health  problems  are  related  to  
our  ever  expanding  waistlines.  The  reasons  for  the  increased  
morbidity  and  mortality  due  to  excess  body  weight   are  high  blood  
pressure,  dyslipidemia,  glucose  intolerance,  and  development  of  
metabolic  syndrome5.  
The  INTERSALT  study  involving  more  than  10000  men  and  
women  reported  that  a  10  kg  increase  in  weight  was  associated  
with  a  3  mmHg  rise  in  systolic  blood  pressure  and  2.3  mmHg  rise  
in  diastolic  blood  pressure6.  In  obese  individuals  the  development  of  
complication  is  highly  correlated  with  intra abdominal  fat  ( visceral )  
than  with  peripheral   ( subcutaneous )  fat6.  So  the  BMI,  most  widely  
used  indicator  of  weight  status  could  not  be  a  much  useful  one  
anymore7.  
In  recent  years  many  cross  sectional  and  prospective  studies  have  
shown  that  the  most  precise  indices  like  Waist  hip  ratio  and   Waist  
height  ratio  are  needed  to  be   focused  more  than  BMI.  In  one  such  
study  of  systemic  review  and  meta  analysis  of  data  on  more  than   
300,000  individuals  from  diverse  populations  across  the  world,         
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it  has  been  proven  that  measures  of  abdominal  obesity  provide  
superior  tools  for  discriminating  obesity  related  cardiometabolic  risk  
compared  with  BMI8.   
After  the  discovery  of  leptin,  a  neuroendocrine  hormone,  the  
concept  of  obesity  has  completely  changed.  Leptin  is  a  peptide  
hormone  of  16  KDa  MW,  having  167  aminoacids9.  It   is  a  product  
of  Ob  gene  secreted  by  adipose  tissue10.  Its  main  function  is  
regulation  of  food  intake,  metabolism,  fat  accumulation  by  acting  
on  its  receptors  in  hypothalamus.  It   also  influences  autonomic,  
cardiovascular,  renal  and   endocrine  functions11. 
Leptin,  the  name  was  derived  from  a  Greek  word  called  leptos  
meaning  thin12.  Since  it  acts  as  an  appetite  suppressant  and  prevents  
excessive  weight  gain,  its  deficiency  leads  to  hyperphagia  and  
obesity13.  So  it  plays  a  key  role  in  regulating  energy  intake  and  
expenditure,  including  appetite  and  hunger,  metabolism  and  
behaviour.   
In  contradictory  to  this,  obesity  is  associated  with  elevated  plasma  
leptin  levels.  Here  the   elevated  leptin  levels  are  not  sufficient  to  
prevent  dysregulation  of  energy  balance,  suggesting  that  obese  
people  are  leptin  resistant.  The  mechanisms  of  leptin  resistance  is  
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still  not  known.  This  resistance  is  only  to  the  energy regulating  
action  of  leptin  in  the  hypothalamus.  So  it  is  called selective  
resistance10  which   means  the  other  peripheral  actions  of  leptin  are  
preserved. 
The  peripheral  actions  of  leptin  include  widespread  activation of  
sympathetic  nervous  system,  sodium  retention  by  kidneys  and 
activation  of  Renin  angiotensin  system.  All  these  actions  of  leptin 
contribute  to  the  development  of  hypertension14.  So  hyperleptinemia  
causes  hypertension   resulting  in  increased   cardiovascular  
complications   in  normal  weight  as  well  as  obese  individuals.   
Anoop  Shankar  and  Jie  xiao  in  their  study  observed  a  positive  
association  between  plasma  leptin  levels  and  hypertension  was  
observed   and   this  association  existed  both  in  normal  weight  and  
overweight / obese  individuals15. 
In  a  cross  sectional  study  done  by  Costas  thomopoulos  and  his  
colleagues,  they  have  found  that  increased  plasma  leptin   is  
independent  of  confounders,  including  body  size  and  metabolic  
parameters14.  In  another  study  also,  done  by  Kawaljit  Kaur  Khokhar  
and  colleagues,  both  normal  weight  and  obese,  hypertensive           
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Pre  menopausal  women  showed  significantly  higher  leptin  levels  
than  their  normotensive  counterparts16.   
So  the  pathophysiological  role  of  leptin  in  the  development  of  
hypertension  might  be  implicated  on  the  adverse  hemodynamic  
regulation  beyond  the  centrally,   obesity  -  mediated  mechanisms  of  
leptin  resistance14.  Thus  it  affects  the  blood  pressure  and  contributes  
to  the  development  of  hypertension  by  not  only  acting  on  energy  
expenditure  but  also    through  sympathetic  activation  in  the  
vasculature  and  at  the  renal  level. 
So  this  study  mainly  concentrates  on  association    between    Serum  
leptin  levels  and    blood  pressure  and  also  its  association  with   
BMI,  Waist   hip  ratio  and  Waist   height   ratio.   
 
 
 
 
 
 
 
    
   
 
 
 
 
 
 
AIMS & OBJECTIVES
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AIM : 
To  study  the  relationship  between  serum  leptin  level  and  Blood  
pressure in  association  with  Age,  Gender,  Body  mass  index,  Waist  
hip  ratio  and  Waist  height  ratio. 
 
OBJECTIVES : 
1. To  compare  Serum  leptin  level  and  Blood   pressure. 
2. To  correlate  Serum  leptin  level  and  Blood  pressure  with  Age, 
Gender,  Body  mass  index,  Waist  hip  ratio  and   Waist  height  
ratio. 
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REVIEW   OF  LITERATURE 
Blood  pressure  is  defined  as  the  force  exerted  by  the  blood   against  
any  unit  area  of  the  vessel  wall.  It  is  usually  measured  in   
millimetres  of  mercury  (mm   Hg)17.  Blood  pressure  unless  otherwise   
specified,  refers  to  the  systemic  arterial  pressure.   
This  pressure  is   not  constant  throughout  the  cardiac  cycle,  the  
highest  pressure   achieved  during  systole  is  systolic  pressure  and  is  
about  120  mm Hg  ,  while  the  lowest  pressure  occurs  in  diastole  is  
diastolic  pressure  which  is  about  80  mm Hg.   
Blood  pressure  is  conventionally  written  as  systolic  pressure   over  
diastolic  pressure  120/80  mm Hg.  One  millimetre  of  mercury   equals  
0.133  KPa,  so  in  SI  units  this  value  is  16.0  /  9.3  KPa18.   
The   mean  pressure  is  the  average  pressure    throughout  the  cardiac  
cycle.  Because  the  duration  of  diastole  is  longer  than  systole,  it  is  
not  the  simple  average  but  is  calculated  as  the  diastolic  pressure  +  
1/3  of  pulse  pressure.  The  difference    between  systolic  and  diastolic  
blood  pressure   is  called  pulse  pressure  and  is  about  40  mm  Hg18.   
 
 
 
 HISTORY  
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Measurement  of  blood  pressure:   
The  first  blood  pressure  measurement  was  done  by   
Rev. Stephen  Hales,  an  English  clergy  man  in  1733  in  the  femoral   
artery  of  a  horse.  He  introduced  a  brass  cannula  into  the  animal’s   
artery  and  it  was  connected  to  a  long  glass  tube  by  the  trachea  of   
a  goose19.   
In  1828,  Poiseuille  devised  the  mercury  manometer  when  he   was  a  
medical  student.  Since  the  density  of  mercury  is  13.6  times   that  of  
water  it  is  used  to  reduce  the  length  of  the  glass  tube20.   
In  1847,  German  physician  Carl  Ludwig  invented  the  kymograph  
and  obtained  the  graphic  tracings  of  blood  pressure20.  In   1896,  
Sciopine    Riva-  Rocci  devised  the  modern  sphygmomanometer  to  
measure  the  human  blood  pressure19.   
In  1905,  Russian    physician    Nikolai  Koratkoff    found    that   blood  
jetting  through  the  partly  occluded  vessel  causes turbulence  in  the  
vessel,  this  sets  up  the  vibrations  heard  through the  stethoscope  and  
the  sounds  are  called  Koratkoff  sounds.  He  described  that  
appearance  and   disappearance  of  the  sound  indicate  systolic  and  
diastolic  pressure17. 
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Blood  pressure  can  be  measured  either    directly  or  indirectly.  In  
direct  method,  blood  pressure  is  measured  by  introducing  a  wide  
bore  needle  into  an  artery  and  connecting  it  to  transducers  and  
oscilloscope  for  recording  the  pressure.  But   this  is  rarely  done  
nowadays.   
Clinically  indirect  method  is  used  for  the  sake  of  convenience.  The   
principle  behind  this  indirect  method  is,  balancing  air  pressure   
against  the  blood  pressure  in  brachial  artery  and  then  estimating  the   
air  pressure  by  means  of  a   mercury  or  aneroid  manometer  or  a   
digital  blood  pressure  recording  device21.   
There   are   three   methods: 
1. Palpatory  method 
2. Auscultatory  method 
3. Oscillatory  method 
In  palpatory  method  the  patient  should  be  in  comfortable,  relaxed,  
sitting  posture.  The  sphygmomanometer  is  placed  at  the  heart  level  
and  the  cuff  is  wrapped  around  the  upper  arm  about  3-4  inches  
above  the  elbow  and  fixed  in  position  by  a  Velcro  attachment.  
Then  the  radial  pulse  is  felt  and  the  cuff  is  inflated  with  the  help  
of  the  pump.  Systolic  pressure  is  indicated  by  the  disappearance  of  
11 
 
the  pulse.  The  diastolic  pressure  cannot  be  measured  by  this  
method.  This  method  is  usually  done  before  auscultatory  method  to  
get  an  idea  about  systolic  pressure. 
In  auscultatory  method,  the  diaphragm  of  the  stethoscope  is  placed  
over  the  region  of  the  brachial  artery  at  the  elbow.  The  cuff  is  
inflated  20  –  30mm  of  Hg  above  the  level  of  the  systolic  pressure  
which  is  obtained  by  the  palpatory  method.  The  pressure  is  now  
slowly  reduced.  As  the  mercury  is  falling,  a  clear  tapping  sound  is  
heard  which  indicates  systolic  pressure.  Then  the  sound  becomes  
murmurish  followed  by  a  clear  loud  sound  and  then  muffles  and  
finally  disappears.  The  disappearance  indicates  the  diastolic  pressure. 
In  oscillometric  method,  when  the  cuff  is  inflated,  the  appearance  
of  the  oscillations  indicate  systolic  blood  pressure,  the  disappearance  
of  oscillations  indicate  diastolic  pressure22.   
Physiological  variations  of  blood  pressure21: 
Systolic  pressure  is  liable  to  variation  due  to  excitement,  emotion,  
exertion  etc.  Hence,  when  it  is  first  checked  in  the  doctors  clinic  it  
may  be  little  higher  than  the  patient’s  usual  pressure.  This  high  
systolic  blood  pressure  observed  in  some  tense  patients  is  called  
white  coat  hypertension.  The  diastolic  blood  pressure  is  more  stable  
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and  doesn’t  vary  much  and  is  considered  to  be  clinically  more  
significant  one. 
1. Age  :    
Systolic  pressure  ( mm Hg ) age 
40 Immediately  after  birth 
70 1  month 
90 4 – 5  years 
110- 120 adult 
140 - 150 Mid 50 
160 After  70  years 
 
2. Sex  :  In  females  before  menopause 3 – 5 mm  lesser  than males 
due  to  estrogen.  After  menopause increase in systolic blood 
pressure  is  more  in  women. 
3. In  emotional  excitement,  anger,  fear,  worry  systolic  pressure  
is  increased  due  to  impulses  from  higher  centres  and  release  
of  adrenalin.   
4. Posture :  Blood  pressure  is  higher  in  standing  position  than  in  
sitting  posture  and  is  lowest  in  supine  posture.   
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5. Gravity: With the heart as the reference  point,  the  blood  pressure  
values  increase  towards  the  feet  but  decrease  towards  the  
head.  For  every  one  cm,  the  rise  or  fall  is  by  0.77  mm Hg.   
6. Digestion: There  is  slight  rise in  systolic pressure  (5-8  mm Hg )  
after  a  meal  lasting  for  about  an  hour. 
7. Sleep:  Pressure is  reduced by about 10- 20  mm Hg  during  sleep. 
8. Exercise:  Systolic  blood  pressure  increases  up  to  180  mm  Hg  
due  to  increase  in  stroke  volume.  In  mild  and  moderate  
exercises  there  is  no  change  in  diastolic  blood  pressure  
whereas  in  severe  exercise  it  actually  falls  because  of  
vasodilatation. 
9. Diurnal  variation  :  Fluctuations  in  blood  pressure  occurs  due  
to  circadian  rhythm.   Pressure   is  highest  in  afternoon. 
10. Surface  area  :  Blood  pressure  is  directly  proportional  to  the  
surface  area.  So  blood  pressure  is  more  in  obese  people. 
11. Respiration:  Blood  pressure  falls  during  inspiration  and  raises  
during  expiration.   
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Factors  affecting  blood  pressure23: 
Arterial  blood  pressure  is  maintained  by  five  important  factors.  
1. Cardiac  output 
2. Peripheral  resistance 
3. Elasticity  of  the  arterial  wall 
4. Blood  volume 
5. Volume  of  the  vascular  space 
Simply  blood  pressure  =  Cardiac  output  x  Peripheral  resistance 
As cardiac output is the product of stroke volume and heart rate, the 
factors which affect these two will affect the cardiac output. The stroke 
volume is affected by preload, afterload and myocardial contractility.  
Heart  rate  is  mainly  affected  by  autonomic  influences. 
Blood pressure is directly proportional to peripheral resistance. The 
resistance mainly depends upon the diameter of the blood vessel, 
viscosity of the blood and velocity of the blood flow. Peripheral 
resistance mainly influences the diastolic pressure more than systolic 
pressure.  
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Elasticity of arterial wall is responsible for the origin and maintenance of 
diastolic pressure. The elastic recoiling property of the arterioles  is  
responsible for  the  conversion  of  intermittent  blood  flow into  an  
continuous  one.  
Increase in blood volume raises both systolic and diastolic pressure, 
whereas a reduction in blood volume decreases the blood pressure. 
Vasodilatation causes reduced blood pressure and vasoconstriction  
causes  elevated  blood  pressure.  
Regulation  of  blood  pressure 23 : 
Blood  pressure  is  not  controlled  by  a  single  mechanism  but  
regulated  by  numerous  interrelated  mechanisms.  They can  be  broadly 
divided  into  three  categories.  They are  short  term,  intermediate  and  
long  term  regulation.  
A. Short  term  regulation: 
a. Neural  :  Regulates  blood  pressure  within  seconds  or  minutes.   
Autonomic  nervous  system  plays  an  important  role  in  short  term 
regulation.  
Baroreceptor  reflex  :  Whenever  there  is an  increase  in  blood  
pressure,  baroreceptors  present  in  carotid  sinus  and  aortic  arch  are  
stimulated,  send  their  impulses  via  sinus  nerve  to  nucleus  tractus  
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solitarious.  This  in  turn  inhibits  the  vasomotor  centre  and  stimulates  
cardio  inhibitory  centre.  Vagal  tone  increases,  sympathetic  tone  
decreases.  This  leads  to  vasodilation,  decreased  cardiac  output,  
decreased  heart  rate  and  thereby  decrease  in  blood  pressure.  
 This  baroreceptor  mechanism  is  highly  adaptable.  Working  range  of  
blood  pressure  for  this  mechanism  is  60-160  mm Hg.  In  
hypertension,  this  mechanism  is  reset  at  a  higher  level  to  maintain  
pressure  at  elevated  levels. 
b. Chemoreceptor  reflex:  Chemoreceptors  present  in  carotid  body  
and  aortic  body  will  respond  to  hypoxia,  hypercapnia  and  acidosis.  
When  blood  pressure  falls  below  60  mm  Hg,  chemoreceptors  are  
stimulated,  impulses  reach  the  vasomotor  centre  via  the  respiratory  
centre  resulting  in  an  increase  in  heart  rate  and  blood  pressure. 
c. Cushing’s  reflex:  Fall  in  blood  pressure  below  40  mm  Hg  
results  in  ischemia  of  central  nervous  system.  This  stimulates  the  
vasomotor  centre  directly  resulting  in  rise  in  blood  pressure.  So  the  
blood  flow  is  restored  and  ischemia  is  relieved.  This  powerful  short  
lived  response  is  also  called  “last  ditch  effort.” 
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B. Intermediate  term  regulation:  
a. Stress  relaxation:  Whenever  vascular  smooth  muscle  is  
stretched  for  prolonged  period  as  a  result  of  increased  blood  
pressure  it  goes  for  relaxation  and  causes  reduction  in  blood  
pressure.  Reverse  changes  takes  place  when  blood  pressure  falls.  It  
is  known  as  reverse  stress  relaxation.   
b. Capillary  fluid  shift  mechanism:  Increase  in  blood  pressure  
causes  more  fluid  filtration  through  the  capillary  wall  into  the  
interstitial  space.   
c. Tissue  fluid  shift  mechanism :  Reduction  in  blood  volume  
results  in  fall  in  blood  pressure.  In  that  situation,  fluid  enters  from 
tissue  space  into  capillary  to  raise  the  blood  volume  and  blood 
pressure. 
C. Long  term  regulation:  
1. Hormonal  mechanism 24 :   
a. Catecholamines:  Nor  epinephrine  is  a  potent  vasoconstrictor,  
so  it  causes  increase  in  both  systolic  as  well  as  diastolic  blood  
pressure.  Epinephrine  :  it  mainly  acts  on  heart.  Net  effect  is  rise  in  
systolic  blood  pressure.  There  is  no  change  in  diastolic  blood  
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pressure.  Both  these  hormones  influence  blood  pressure  in  
physiological  as  well  as  stressful  conditions. 
b. Glucocorticoids  :  Through  the  permissive  action,  they  sensitise  
the  vascular  smooth  muscle  to  the  action  of  catecholamines.  They  
retain  sodium,  chloride  and  water  by  stimulating  their  reabsorption  
from  distal  nephron.   
c. Mineralocorticoids:  Aldosterone  retains  sodium,  chloride  and  
water  by  stimulating  their  reabsorption  from  kidney  thereby  
increasing  the  blood  volume  and  blood  pressure. 
d. Thyroid  hormones:  They  regulate  blood  pressure  by  acting  on  
the metabolism and  also  by  potentiating  the  action  of  catecholamines.   
e. Angiotensin  II:  It  is  a  potent  vasoconstrictor  that  increases  the  
blood  pressure. 
f. Vasopressin  :  By  increasing  the  volume  of  blood,  it  increases  
the  blood  pressure.  It  is  also  a  powerful  vasoconstrictor.   
g. Serotonin, Endothelin: Both  are vasoconstrictors  thereby  increase  
the  blood  pressure. 
h. Histamine,  Endothelium  derived  relaxing  factor:  Both  are  
vasodilators  cause  fall  in  blood  pressure. 
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i. Atrial  natriuretic  peptide:  Acts  on  proximal  convoluted  tubule  
and  prevents  absorption  of  sodium  and  water  thereby  reduces  blood  
volume  and  blood  pressure.   
Kidney  plays  an  important  role  in  long  term  control  of  blood 
pressure  by  pressure  natriuresis  and  pressure  diuresis.  It  exerts  its 
effect  through  Renin – Angiotensin – Aldosterone  axis.  
Thus  blood  pressure  is  effectively  controlled  by  many  factors. Any  
derangement  in  these  mechanisms  will  result  in  sustained elevation  
of  blood  pressure  which  is  called  hypertension. 
Hypertension  is  classified  into  2  types,  
1. Primary   or  essential  hypertension:  In  which  the  cause  for  
increase  in  blood  pressure  is  not  known.  It constitutes  about          
90-95%  0f  patients. 
2. Secondary  hypertension:  In  this  type  the  increase  in  blood  
pressure  is  caused  by  diseases  of  kidney,  endocrine  or  some  other  
organs.  It  comprises  5-10  %  of  cases25. 
According  to  the  clinical  course,  both  essential  and  secondary  
hypertension  may  be  benign  or  malignant.  Benign  hypertension  is  
moderate  elevation  of  blood  pressure  and  the  rise  is  slow  over  
years.  Malignant  hypertension  is  marked  and  sudden  increase  of  
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blood  pressure  to  200/140  mm Hg  or  more  in  a  known  hypertensive  
patient  or  in  a  previously  normotensive  individual26.   
Etiological  factors: 
Essential  hypertension:  ( 90  % )26 
1. Genetic  factors  including  Mendelian  forms  of  hypertension 
2. Racial  and  environmental  factors:  A  number  of  environmental  
factors  have  been  implicated  in  development  of  hypertension  
including  salt  intake,  obesity,  skilled  occupation,  higher  living  
standards  and  individuals  under  high  stress. 
3. Risk  factors  modifying  the  course:   
1. Age  :  Younger  the  age,  lower  the  life  expectancy. 
2.   Sex: Females with  hypertension  appear  to  do  better  than  males. 
3. Atherosclerosis:  Factors  associated  with  this,  like  cigarette  
smoking,  elevated  serum  cholesterol,  glucose  intolerance,  obesity  
and  excess  alcohol  intake   will  influence  hypertension. 
Secondary  hypertension:  ( 10 % )1 
1. Renal  -  Renovascular  and  Renal  parenchymal  disease. 
2. Endocrinal – Adrenocortical  hyperfunction  including  primary      
Aldosteronism, Cushing syndrome, Pheochromocytoma,  
Hyperparathyroidism,  Hypothyroidism,  Acromegaly. 
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3. Oral  contraceptive  pills  and  other  medications. 
4. Coarctation  of  aorta 
5. Neurogenic  causes 
6. Obstructive  sleep  apnoea  syndrome 
7. Hypertension  during  pregnancy 
Pathogenetic  mechanisms   behind  the  development  of  hypertension  
are  explained  by  many  theories.  They suggest that increase  in  blood  
volume  and  Cardiac  output,  high  plasma  level  of  Catecholamines   
producing  vasoconstriction,  altered  responsiveness  to  renin  release   
and   decreased  adrenal  response  to  Angiotensin  II. 
Risks  influencing  prognosis  in  patients  with  hypertension  include   
systolic  and  diastolic  blood  pressure  levels,  age  of  the  patient  and  
associated  comorbid  conditions  like diabetes mellitus,  abdominal  
obesity,  dyslipidemia,  metabolic syndrome,  smoking  and  alcohol. 
Patients  having  chronic  hypertension  are  more  prone  to   develop  
target  organ  damage.  Left  ventricular  hypertrophy,  carotid  wall   
thickening  or  plaque,  reduced  GFR,  microalbuminuria,  ankle  brachial  
blood  pressure  index  <  0.9  will  be  present  subclinically  in  these  
patients. 
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Established  target  organ  damages  include27, 
Cerebrovascular  accidents  –  stroke,  cerebral  haemorrhage,  transient  
ischemic  attacks. 
Heart  disease:  Myocardial  infarction,  angina,  congestive  cardiac  
failure. 
Renal  disease:  Chronic  kidney  disease 
Peripheral  arterial  disease,  hypertensive  retinopathy,  papilloedema. 
The  proposed  mechanisms  involved  in  the  development  of  target  
organ  damage  are  endothelial  cell  dysfunction  and  vascular  
remodelling.  By  decreasing  lumen  diameter  in  the  peripheral  
vasculature,  inward  eutrophic  remodelling  increases  systemic  
vascular  resistance,  the  hemodynamic  hallmark  of  diastolic  
hypertension. 
Neural  mechanisms  are  also  involved.  In  young  adults,  primary  
hypertension  is  consistently  associated  with  increased  heart  rate,  
cardiac  output,  plasma  and  urinary  norepinephrine  levels,  regional  
norepinephrine  spillover,  peripheral  postganglionic  sympathetic  nerve  
firing,  α  adrenergic  receptor  mediated  vasoconstrictor  tone  in  
peripheral  vasculature28. 
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Initial  evaluation  of  patients  with  hypertension1: 
1. Measurement  of  blood  pressure 
2. Assessment  of  target  organ  damage 
3. Detection  of  identifiable  cause  for  secondary  hypertension 
Measurement  of  blood  pressure  includes  home  and  ambulatory  
monitoring (ABPM).  It  provides  automated  measurements  of  blood  
pressure  during   a  24  hour  period  while  patients  are  engaged  in  
their  usual  activities  and  sleep.  It  helps  to  rule  out  white  coat  
hypertension  and  masked  hypertension.  In  masked  hypertension,  
pressure  recorded  in  the  hospital  is  normal  whereas  blood  pressure  
recorded  during  daily  activities  is  increased  because  of  job  /  home  
stress,  tobacco  use  or  other  adrenergic  stimulation  that  dissipates  
when  they  come  to  hospital. 
Laboratory  investigations  include  repeat  measurements  of  renal  
function  that  is  serum  urea,  creatinine,  microalbuminuria,  blood  urea  
nitrogen  ( BUN ),  serum  electrolytes,  fasting  glucose,  and  lipid  
profile,  electrocardiogram    have  to  be  done  immediately  after  
diagnosis  and  after  introducing  a  new  antihypertensive  agent  and  
then  annually29. 
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Obesity  related  hypertension  deserves  special  mention  here.  With  
weight  gain,  reflex  sympathetic  activation  may  be  an  important  
compensation  to  burn  the  fat  but  at  the  expense  of  sympathetic  
over  activity  in  target  tissue  that  produces  hypertension29. 
Hypertensive  patients  with  metabolic  syndrome  with  or  without  
diabetes  mellitus  have  near  maximal  rates  of  sympathetic  firing.  
The  precise  stimulus  include  leptin,  other  adipokines  and  
angiotensin  II29.    So  prevention  and  treatment  of  obesity  are  
important  for  reducing  blood  pressure  and  cardiovascular  disease  
risk. 
Health  –  promoting  lifestyle  modifications  are  recommended  for  
individuals  with  pre-hypertension  and  as  an  adjunct  to  drug  therapy  
in  hypertensive  individuals.  Dietary  modifications  that  effectively  
lower  blood  pressure  are  weight  loss,  reduced  NaCl  intake,  
increased  potassium  intake,  Diet  rich   in  fruits,  vegetables,  and   
low– fat  dairy  products  with  reduced  content  of  saturated  and  total  
fat,  moderate  alcohol  consumption  and  an  overall  healthy  dietary  
pattern  and    regular  aerobic  activity  like  brisk  walking  for  30     
min / day29. 
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OBESITY 
Nutrition  is  an  essential  interaction  of  an  organism  with  the   
environment.  Nutrients  apart  from  providing  energy  for  survival,  
signal  the  organism  in  diverse  ways  and  this  in  turn  affects  their  
use  and   storage30.    
Nutrition  underpins  health  and  affects  susceptibility  to  disease.  Both  
malnutrition  and  obesity  put  an  organism  at  risk.  The  factors  that   
determine  nutritional  status  of  an  individual  are  the  genetic  
background,  the  environment,  the  phase  of  life  cycle,  the  levels  of  
physical  activity  and  the  presence  of  disease30. 
Anything  that  leads  to  a  continuous  imbalance  between  food  intake  
and  energy  consumption  will  lead  to  obesity  (positive  energy  
balance)31.  Obesity  represents  a  major  medical  problem  in  most  of  
the  developed  and  developing  countries.   
Worldwide,  at  least  2.8  million  people  die  each  year  as  a result  of  
being  overweight  or  obese,  and  an  estimated  35.8 million (2.3%)  of  
global  DALYs  (Disability  adjusted  life  year)  are  caused  by  
overweight  or  obesity.  In  high  income  countries  women's  obesity  
prevalence  was  similar  to  that  of  men.  In  low  and  lower  middle  
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income  countries,  obesity  among  women  was  approximately  double  
that  among  men32. 
Obesity  is  defined  as  a  state  of  excess  adipose  tissue  mass  and  is  
best viewed  as  a  syndrome  or  group  of  diseases  rather  than  as  a  
single disease  entity33.  The  importance  of  this  state  is  that,  its  
prevalence  is  increasing  worldwide  and  it  is  associated  with  serious  
morbidity.  However  the  pathogenesis  of  obesity  in  vast  majority  of  
humans  is  unknown  and  remains  unexplained. 
Obese  people  are  more  likely  to  develop  a  number  of  diseases  
including  hypertension,  diabetes  mellitus,  gall  stones,  cancer,  non  
alcoholic  fatty  liver  disease,  obstructive  sleep apnoea,  osteoarthritis  
knee,  and  metabolic  abnormalities33,34.    
Endocrine consequences  of  obesity  are  insulin  resistance,  diabetes  
mellitus, hypothyroidism,  gonadal  dysfunction,  decreased  pituitary  
hormone secretion  ( particularly  growth  hormone )33.  It  is  not  a  
single  disorder  but  a  common  manifestation  of  wide  variety  of  
disorders  that  affect  energy  balance  in  some  way.  Their  life  span  is  
significantly  shortened.  
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Uncorrected  obesity  often  leads  to  cardiac  hypertrophy,  reduced  
diastolic  compliance,  ventricular dysfunction,  increased  blood  
pressure,  arteriosclerosis  and  other  vascular  complications35.  In  
addition  to  that,  it  dramatically  enhances  the  chances  of  cluster  of  
metabolic  diseases  such  as  insulin  resistance,  hyperinsulinemia, 
diabetes  mellitus,  hyperlipidemia,  hyperuricemia  and  low plasma  high  
density  lipoprotein  cholesterol,  collectively  known  as  the  metabolic  
syndrome36. 
Factors   influencing  obesity: 
Environmental   and  genetic  factors  play  a  key  role  in  obesity.  
Cultural  factors  relating  to  both  availability  and  composition  of  the  
diet,  changes  in  the  level  of  physical  activity  both  will  have  
important  impact  on  weight  gain.  In  industrial  societies,  obesity  is  
most  common  among  poor  women  whereas  in  underdeveloped  
countries,  wealthier  women  are  more  often  obese34.  
The   prevalence  is  high  among  women  and  children34.  In children,  
obesity  correlates  to  some  degree  with  time  spent  on  watching  
television.  Obesity  is  promoted  by  high  fat  diets  combined  with  
diets  rich  in  rapidly  absorbed  simple  carbohydrates.   
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Sleep  deprivation  leads  to  increased  obesity.  Recent  advances  says  
that  changes  in  gut  microbiome  with  capacity  to  alter  energy  
balance  and  a  possible  role  for  obesigenic  viral  infections  continues  
to  receive  sporadic  attention34.  
Initially  the  criteria  used  for  assessing  obesity  is  defined   on  purely  
statistical  grounds  as  a  weight  that  is  20% or  more  above  the  
average  weight  per  height33.  Over  the  past  decade,  calculation  of  
BMI  has  evolved  as  a  more  standard  measurement  used  to  correlate  
weight  with  morbidity  and  mortality.  
BMI  is  the  most  important  and  widely  used  tool  in  the  world  for  
indicating  fat  levels  in  the  human  body37,  and it  is  officially  
recognised  by  the  World  Health  Organisation.  BMI  is  calculated  by  
determining  weight  in  kilogram and  dividing  it  by  the  height  in  
meters  squared38.  At  a  similar  BMI,  women  have  more  body  fat  
than  men.  According  to this  measurement  body  weight  has  been  
divided  into  four classes.  
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Classification  of  BMI:34 
BODY MASS INDEX CLASSES 
<19 Underweight 
19 - 25 Normal 
26 - 30 Over weight / pre obese 
>30 Obese 
>40 Extreme obesity 
 
A  BMI  of  < 19  is  considered  underweight  and  carries  a  modestly  
increased  risk  of  morbidity  and  mortality.  Overweight  category  
statistically  carries  a  slightly  increased  risk  of  co  morbidities  such  
as  diabetes  mellitus  and  cardiovascular  disease  compared  with  the  
risk  in  normal  weight  individuals.   
The  obese  category  is  further  subdivided  into  class  I  (BMI 30 to 39) 
class  II  ( BMI 40 to 49 ),  class  III ( BMI >50 ).  They  carry  respective  
risks  of  co morbidities  that  are  moderate,  severe  and  very  severe  
respectively33.  
At  present  60 %  of  male  population  and  50 %  of  female population  
have  a  BMI  of  more  than  25  which  is  having increased  risk  of  
morbidity  and  mortality33.  BMI  is  used  as  a most  common   
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predictor,  because  it  is  the  simplest  measurement  to  calculate  in  the  
clinic. 
A  second  approach  defining  the  obese  state  involves quantification  
of  adipose  tissue,  either  directly  or  indirectly.  This include  
measuring  skin  fold  thickness,  waist  circumference, waist to  hip  
ratio.  Values  are  obtained  for  a  reference  group.  Obesity  is  defined 
as  levels  of  adiposity  exceeding  the  reference  group33.      
Accumulation  of  adipose  tissue  in  different  depots  has  distinct 
consequences.  Thus  many  of  the  complications  of  obesity  like   
hypertension,  insulin  resistance ,  diabetes  mellitus  and  hyperlipidemia  
are  linked  to  the  amount  of  intra  abdominal  fat  rather  than  to  
lower  body  fat  (buttocks,  leg)  or  subcutaneous  fat33.   
However,  while  BMI  is  an  indicator  of  total  fat  levels,  it  provides  
no  indication  of  how  fat  is  distributed  in  the  body.  The  manner  in  
which  fat  is distributed  in  the  body  is  important,  as  it  has  been  
found that  fat  which  is  stored  in  and  around  internal  organs  (such  
as  the  liver,  kidneys,  pancreas  and  heart)  tends  to  be significantly  
more  harmful  than  fat  which  is  stored peripherally,  particularly  in  
the  form  of  subcutaneous  (under  the  skin)  fat.  
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The  mechanism  behind  this  is,  because  of  the  fact  that  intra  
abdominal   adipocytes   are  lipolytically  more  active  than  those  from  
other  depots34.  This  activity  can  have  harmful  effects  such  as  
induced  insulin  resistance,  impaired vascular  function  and  
inflammation.  Release  of  free  fatty acids  into  the  portal  circulation  
has  adverse  metabolic  actions,  especially  on  the  liver.   
Abdominal  fat,  typically  evident  on  physical  examination  can be  
estimated  by  determining  the  waist  to  hip  ratio,  skin  fold  thickness,  
recently  waist  to  height  ratio , densitometry  ( underwater  weighing ),  
computerised  tomography,  magnetic  resonance  imaging  and  electrical 
impedance33,34. 
Waist  circumference: 
Waist  circumference  measurement  is  one  of  the  easiest  way  of  
determining  the  abdominal  adiposity.  To  measure  the  waist 
circumference  the  most  consistently  used  site  was  World  Health 
Organization  ( WHO )  definition  of  halfway  between  the  lower  rib 
margin  and  the  iliac  crest39. 
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The  recommended  limits  of  waist  circumference  set  by  the  World 
Health Organisation  for  both  males  and  females,  also  specifies  the  
corresponding  risk  categories  for  metabolic  disease: 
Metabolic Risk 
Category 
Males: Waist 
Circumference 
Females: Waist 
Circumference 
Normal ≤  94 cm ≤ 80 cm 
Increased Risk >94 cm >80 cm 
Greatly Increased 
Risk 
> 102 cm > 88 cm 
 
From  this  table  it  is  clear  that  men  should  strive  to maintain  a  
waist  circumference  of  94  cm  or  less,  and  for  women  the  
corresponding  goal  is  80  cm40.  
Even  though  waist  circumference  is  a  reliable  indicator  of 
cardiometabolic  risk  in  defined  populations,  it  has  been  found  that  
a  healthy  waist  circumference  in  one  ethnic  group  can  differ  from  
that  in  another.  For  example,  Asians  have  a  higher  metabolic  risk  
than  Europeans  at  any  given  waist  circumference,  due  to  the  fact  
that  Asians  tend  to  carry  more  truncal   fat  than  Europeans  for  any  
given  BMI41.  This  is  the  main  disadvantage  of measuring  waist  
circumference  alone  as  a  screening  tool. 
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Waist  to  Hip Ratio: 
A  rough  index  of  the  relative  amounts  of  visceral  and  abdominal  
fat  is  the  waist  to  hip ratio.  This  is  calculated  by dividing  the  waist  
circumference  by  the  hip  circumference.  Hip circumference  is  taken  
as  the  largest  standing  horizontal circumference  of  the  buttocks42.  
Waist  hip  ratio  is  commonly abbreviated  as  WHR.  Ratio  >  0.72  is  
considered  abnormal.  It  is  accurately  quantified  by  dual  energy       
X –ray  absorptiometry  ( DEXA)  scanning  or  computed  tomography33.   
Points  to  be  noted  while  measuring  the  waist  and  hip 
circumference: 
 A   flexible  but  not  a  stretchable  tape   should  be  used. 
 It  has  to  be  measured  directly  on  the  skin,  not  over  the  
clothing. 
 It  has  to  be  ensured  that  the  tape  is  horizontal  and  correctly  
placed. 
 The  person  whose  measurement  is  taken  should  stand  straight.  
 The  tape  should  be  held  lightly  so  as  not  to  compress  the  
skin. 
 The  person  should  relax  his / her  muscles,  breath  out  fully 
while  the circumference  is  being  measured. 
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 A  record  of  the  serial  measurements  can  be  kept  to  track  the 
progress  over  time. 
 For  measurements  taken  over  a  period  of  time,  it  should  be  
done  at  the  same  time  of  the  day. 
Body  fat  distribution  can  alternatively  be  described  as pear  shaped    
( low WHR )  and  apple  shaped  ( higher WHR )33. ‘Apple’ shaped  
people  store  fat  centrally  (around  the  waist),  while  ‘pear’  shaped  
people store  fat  peripherally  (around  the  hips  and  buttocks).  These  
shapes  become  more  obvious  and  pronounced  in  the  overweight  and  
obese  categories  of  BMI.  
An  apple  shaped  person  of  the  same  gender,  age  and ethnicity  as  a  
pear  shaped  person,  and  with  the  same  BMI,  will tend  to  have  a  
much  greater  risk  of  developing  cardiometabolic diseases  such  as  
diabetes,  dyslipidaemia,  hypertension,  coronary heart  disease  and  
stroke43.  
The  relative  risk  of  morbidities  associated  with  obesity  is  lower  
when  the  WHR  is  < 0.8  and  it  is  more  when  the  WHR  is  > 134,44.  
Hence,  the  metabolic  syndrome,  which is  a  clustering  of  obesity  and  
other  cardiovascular  risk  factors is  more  likely  to  be  associated  with  
visceral  obesity33.  
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Waist  to  hip  ratio  is  the  best  predictor  and  it  is  noteworthy  that  
increased  WHR  is  associated  with  increased  incidence  of  
cardiovascular  morbidity  in  women  even  at  the  relatively  low  BMI  
of  2533.  Visceral  obesity  is  associated  with  increased  occurrence  of  
hypertension  and  an  atherogenic  lipid  profile  both  of  which  
contribute  to  the  development  of  cardiovascular  disease. 
 It  is  known  that  the  waist-to-hip  ratio  can  predict  mortality,  as  
BMI,  but  the  taller  we  are,  the  longer  we  live.  So  by  adding this  
to  the  waist-to-hip ratio, “people  who  are  taller,  their  waist-hip  ratio  
can  be  bigger,  because  the  height  is  reducing  their  risk." 
Waist  to  height  ratio: 
Another  measure  of  distribution  of  body  fat  is  waist  to  height ratio.  
The  waist  to  height  ratio  of  a  person  is  defined as  the  person's  
waist  circumference,  divided  by  the  person's  height.  The normal  
waist  to  height  ratio  should  be  ≤ 0.544.   So  it  is  clear  that  men  and  
women  should  strive  to  keep  their  waist  circumference  to no  more  
than  half  their  height.  The  most  consistently  used  abbreviation  for  
this  waist  to  height  ratio  is  WHtR39. 
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A  systemic  review  and  meta  analysis  done  by  M. Ashwell   et  al  
had  revealed  that  waist  height  ratio  was  a  better  predictor  than  
waist  circumference  for  diabetes,  dyslipidemia,  hypertension,  and  
cardiovascular  disease  risk  in  both  genders  in  populations  of  various  
nationalities  and  ethnic  groups.  They  had  analyzed  data  of  more  
than  300,000  individuals  from  diverse  populations  across  the  world  
and  suggested  that  measures  of  abdominal  obesity  provide  superior  
tools  for  discriminating  obesity  related  cardiometabolic  risk  
compared  with  BMI.  Moreover,  waist  height  ratio  has  better  
discriminatory  power  than  waist  circumference8.  
A  systemic  review  of  78  cross  sectional  and  prospective  studies  
exploring  waist  height  ratio  waist  hip  ratio or  body  mass  index  as  
predictors  of  diabetes  and  cardiovascular  disease  published  between  
1950  and  2008.  This  review  employed  specificity  and  sensitivity  
comparisons,  indicated  that  waist  to  height  ratio  could  be  a  useful  
screening  tool,  with  a  weighted  mean  boundary  value  of  0.5. This   
supports  the  simple  public  health  message  “ keep  your waist  
circumference  to  less  than  half  your  height39”.   
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There  is  an  another  new  indicator   introduced  recently,  waist-to-hip-
to-height ratio  (WHR  divided  by  height).  It  is  abbreviated  as 
WHHR.  This  is  also  one  of  the  best  predictor  for  cardiovascular  
morbidity  and  mortality.  It  needs  to  be  tested  in  more  diverse  
population. 
Rather  than  BMI  alone,  if  it  is  added  along  with  waist  hip  ratio,  
waist  height  ratio  and  waist  hip  height  ratio,  then  the                    
risk – prediction  tool  would  become  more  accurate37,39,44.  
These   indicators  like  waist  circumference,  waist  hip  ratio  and  waist  
height  ratio,  collectively  known  as  waist  metrics,  they  describe  the  
extent  of  central  fat  distribution,  and  for  this  reason  they  are  a  
valuable  complement  to  BMI.  However,  they  are  not  a substitute  for  
BMI.  While  these  waist  metrics  take  fat  distribution  into  account  
and   BMI  does  not,  BMI  takes  total  fat  into  account  while  waist  
metrics  do  not6,33.  So,  when  used  together,  these  measures  tend  to  
provide  a  more  reliable  indicator  of  cardiometabolic  risk  than  either  
measure  used  alone. 
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Therapy  for  obesity6: 
Assessment  of  overweight  /  obese  patients  should  include: 
1. H/o  weight  gain  and  maximum  body  weight 
2. Consideration  of  medications  that  contribute  to  weight  gain, 
such  as  corticosteroids,  thiazolidinediones,  antipsychotic agents. 
3. Previous  approaches  to  weight  reduction 
4. Patterns  of  food  intake,  including   binge  eating 
5. Physical  activity  levels 
On  examination, 
1. Measurement  of  weight,  height,  waist  circumference. 
2. Calculation  of  BMI,  waist  to  hip  ratio,  waist  to  height ratio. 
3. Evaluation  of  blood  pressure,  glycemia,  cholesterolemia, liver  
and  cardiovascular  function 
4. Associated  signs  and  symptoms  to  rule  out  genetic deficiencies  
should  be  performed. 
The  treatment  options  for  weight  loss  are: 
1. Lifestyle  modification 
a. Diet  
b. Exercise  
c. Behavioural  modification 
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2. Pharmacotherapy 
3. Bariatric  surgery 
The  discovery  of  leptin  held  great  promise  as  a  direct therapy  for  
obesity.  Although  leptin  effectively  reduces  body  weight  in  rodents,  
high  pharmacologic  doses  elicit only  moderate  weight  loss  in  obese  
humans.  This  is because  selective  resistance  to  its  weight  reducing  
action  in obese  people.  However  a  24  week  proof  of  concept  
clinical  study  has  demonstrated  that  the  combination  of leptin  and  
pramlintide  ( which  is  an  amylin  analogue  drug  used  in treatment  of  
type  2  Diabetes  mellitus)  produced  significantly  greater  weight  loss  
compared  to  leptin,  pramlintide  alone6.  
The  advertisements  for  miracle  weight  loss  programs  raise  false  
hopes  because  the  total  energy  of  the  body  will  only  decrease  if  it  
does  work  on  the  external  environment  or  transfers  heat  or  waste  
materials  to  the  environment.  Whatever  maybe  the  cause  for  the  
obesity,  behaviour   modification  to  decrease  the  food  intake  and  
moderate  exercise  to  increase  caloric  expenditure  represent  the  
effective  management45.  
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We,  human  beings  eat  food  intermittently,  most  often  three times  a  
day.  For  survival,  continuous  supply  of  energy  is required.  So  the  
ability  to  store  excess  energy  is  essential. This  is  done  by  our  fat  
cells  which  reside  within  widely distributed  adipose  tissue  depots.  
The  fat  cells  are  adapted  to  store  excess  energy  efficiently  as  
triglycerides  and  release  stored  energy  as  free  fatty  acids  whenever  
needed.  This  is  necessary  for  humans to  survive  in  starvation  that  is  
why  this  physiological system  is  well  orchestrated   through  endocrine  
and  neural  pathways. 
Physiologic  regulation  of  energy  balance: 
The  effector  arms  of  energy  intake  and expenditure  are  regulated  by  
both  endocrine  and  neural components  that  regulates  the  body  
weight.  The  system  is very  complex  even  a  small  imbalance  
between  energy  intake  and  expenditure   will  result  in  large  changes  
in  body  weight.  For  example  a  0.3 %  positive  balance  over  30  
years  would  result  in  a  9  kg  weight  gain34. 
This  regulation  cannot  be  done  easily  by  calorie  counting  in  
relation  to  physical  activity.  If  there  is  any alteration  in  the  stable  
weight  of  an  individual  by  forced  overfeeding  or  food  deprivation,  
the  physiological  changes  include,  increase  in  appetite  and  fall  in  
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energy  expenditure  with  weight  loss  and  reverse  occurs  with  
overfeeding. 
The  compensatory  mechanism  frequently  fails,  permitting  obesity  to  
develop  when  food  is  abundant  and  physical  activity  is  limited.  
These  adaptive  responses  are  regulated  mainly  by  the  adipose  tissue  
derived  hormone  leptin34.  It  predominantly  acts  in  hypothalamus  to  
reduce  appetite  and  increase  energy  expenditure.  Thus  it  acts  as  a 
neuroendocrine  hormone. 
Hypothalamus  in  brain  is  the  important  centre  in  regulation  of  food  
intake  which  is  influenced  by  many  factors.  Signals  acting  on  this  
hypothalamic  centre  include  neural  afferents,  hormones  and  
metabolites.  Among  them  vagal  inputs  are  important  one,  they  bring  
information  from  viscera,  such  as  gut  distension.  Hormonal  signals  
include  insulin,  leptin,  cortisol  and  gut  peptides  like  peptide  YY, 
ghrelin  and  cholecystokinin.  
Metabolites,  including  glucose,  can  influence  appetite, as  seen  by  the  
effect  of  hypoglycaemia  to  induce  hunger.  All  these  hormonal,  
metabolic,  and  neural  signals  act  on  hypothalamus  to  influence  the  
expression  and  release  of  peptides  like  Neuropeptide  Y,  Agouti  
related  protein,  α  melanocyte  stimulating  hormone  and  melanin  
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concentrating  hormone  integrated  with  catecholaminergic,  
seratonergic,  endocannabinoid  and  opioid  signalling  pathways34.  
Psychological  and  cultural  factors  also  play  a  role  in  the final  
expression  of  appetite.  Apart  from  the  rare  genetic  syndromes  
involving  leptin,  its  receptors  and  the  melanocortin  system,  specific  
defects  in  this  complex  appetite  control  network  that  influence  
common  cases  of  obesity  are  not  well  defined.  
The  components  of   Energy  expenditure  are34: 
1. Resting  or  basal  metabolic  rate 
2. Energy  cost  of  metabolizing  and  storing  food 
3. Thermic  effect of  exercise 
4. Adaptive  thermogenesis 
In  daily  energy expenditure,  basal  metabolic  rate  accounts  for  70%.  
Physical   activity  contributes  5-10%34.  Thus  a  significant  component  
of  daily  energy  consumption  is  fixed.  Any  alteration  in  this  
physiological  system  like  nutritional  abundance  and  sedentary  life  
style  influenced  by  genetic  endowment  results  in  excess  adipose  
tissue  energy storage  and  produces  adverse  health  consequences. 
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It  has  been  long  understood  that  increased  energy  intake   without  
increase  in  energy  expenditure  is  associated   with  obesity.  This  is  
characterised   by  increased   adiposity  in  terms of  both  the  number  
of  adipocytes   and   their  fat  content.  There  are  2  forms  of  adipose  
tissue,  brown  adipose  tissue  and  white  adipose  tissue.    
Brown  adipose  tissue  plays  an  important  role  in  thermogenesis46.  It  
expends  stored energy  as  heat.  In  brown  adipose  tissue,  hydrogen  
ion  gradient  in  the oxidative  respiratory  chain,  is  dissipated  by  a  
mitochondrial  uncoupling protein  (UCP -1)  and  the  energy  is  
released  as  heat34.  Thus  brown  adipose  tissue  takes  part  in  adaptive  
thermogenesis  and  plays  an  important  role  in  energy metabolism  in  
mammals. 
Leptin  increases  the  metabolic  activity  of  brown  adipose  tissue  via  
activating  the  sympathetic  nervous  system.  Identification  of  
functional brown  adipose  tissue  in  many  adults  using  PET  imaging  
has  increased interest  in  the  implications  of  the  tissue  for  
pathogenesis  and  therapy  of  obesity34. 
In  contrast  to  brown  adipose  tissue,  white  adipose  tissue  is  used  to  
store  energy  in  the  form  of  lipids.  This  is  useful  for  cushioning,  
for  example  in  orbits  surrounding  the  eyeballs.  It  also  acts  as  a  
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classic  endocrine  organ  that  releases  numerous  molecules  in  a  
regulated  fashion.  The  tissue   is  composed  of  several  cell  types.  
The  triglyceride  storing  cell  is  called  adipocyte46. 
Adipocyte   differentiation  is  promoted  by  a  transcription  factor  
called  sterol  regulatory  element  binding  protein  1c  (SREBP – 1c).  
An  increase  in  food  consumption  leads  to  activation  of  SREBP – 1c  
and  causes  conversion  of  preadipocytes  into  small  adipocytes.  This  
also  upregulate  enzymes  within  the  adipocyte   to  allow  storage  of  
excess  fat46. 
Adipose   tissue   produces  paracrine  and  endocrine  hormones  
including  energy  balance  regulating   hormone  leptin,  adiponectin,  
resistin  ( collectively called as  adipokines),   cytokines  such  as  tumour  
necrosis  factor,   interleukin  6,  a  component  of  the  blood  pressure  
regulating  system  angiotensinogen,   acylation  stimulating  protein,  
growth  factors,  compliment  factors  such  as  factor  D,  prothrombotic  
agents  such  as  plasminogen  activator  inhibitor46-48.  These  factors,  
and  others  not  yet  identified,  play  a  role  in  the  physiology  of  lipid  
homeostasis, insulin  sensitivity,  blood  pressure  control,  coagulation,  
vascular  health  and  are  likely  to  contribute  to  obesity – related  
pathologies.  
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The  main  molecule  among  them  to  carry  information  about  the  fat  
stores   is  leptin.  In  addition  to  white  adipose  tissue,  leptin  is  also  
produced  by  brown  adipose  tissue,  placenta,  ovaries,  skeletal  
muscle,  stomach,  mammary  epithelial  cells,  bone  marrow,  pituitary  
and  liver43,49-51.  This  is  responsible  for  the  considerable  variation  in   
leptin  concentrations  among  persons  with  the  same  BMI.   
History52: 
The  original  notion  of  homeostatic  regulation  of  energy  balance  
dates  back  to  Lavoisier  and  Laplace.  The  role  of  brain  was  
determined  later  from  clinical  observations  and  was  confirmed  by  
stereotaxic  lesions  of  different  regions  of  brain.     
Hypothalamic  feedback  loop  in  regulating  body  energy  stores  was  
postulated  later  with  many  theories.  One  such  theory  was   
glucostatic  theory  in  which  blood  glucose  was  said  to  be  the  
sensed  signal  for  the  feedback  loop,  proposed  by  Jean  Mayer.   
Then  Kennedy  postulated  the  lipostatic  theory  which  is  having  a  fat 
metabolism  factor. 
Subsequently  Hervy  performed  the  parabiosis   studies  and  confirmed 
that  blood  borne  signals   coming  from  the  adipose  tissue  regulates  
the food  intake  and  body  weight.  Not  too  long  after  Douglas  
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Coleman  at  the Jackson  laboratory  performed  the  seminal  parabiosis  
studies  using  single gene  mice  models  of  obesity  and  diabetes12.  
Ob/ob  gene  encoded  a hormone  whereas  db/db  gene  encoded  the  
receptor  for  that  particular hormone.  
He  concluded  that  the  hormone  was  secreted  by  the  adipose  tissue, 
transported  by  the  blood  and  received  by  its  receptor  in  the  
hypothalamus.  This  laid  the  foundation  for  positioning  cloning  
studies  of ob  and  db  genes  that  laid  to  the  publication  of  the  
discovery  of  leptin  in 199410  by  Jeffrey  M. Friedman,  Rudolph  
Leibel  at  the  Rockefeller  university  together  with  Douglas  Coleman.  
Dr. Friedman  won  the  time magazine,  Best  of  Science  in  1994  and  
the  Albert  Lasker  Basic  Medical Research  Award  in  2010  for  his  
discovery  of  Leptin. 
Structure  of  leptin:  
Leptin  is  a  peptide  hormone  of  16  KDa  MW,  having  167  amino 
acids10.  The  gene  responsible  for  leptin  production  is  ob  gene. 
Leptin belongs  to  cytokine  family of  proteins  like  tumour  necrosis  
factor  α , interleukin  6.  Nuclear  magnetic  resonance  and  crystal  
structure  analysis revealed  a  four  helix  bundled  structure  for  leptin  
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with  four  antiparallel  α helices  linked  with  two  long  crossover  arms  
and  one  short  loop35.  
Leptin metabolism: 
Leptin  circulates  in  bloodstream  as  a  free  protein53.  It  shows  a  
diurnal  rhythm with  minimal  values  during  the  day  time  and  a  
nocturnal  rise  with maximal  values  during  early  sleep  to  mid  
sleep13. Leptin concentration  varies  among  persons  with  the  same  
BMI  suggesting  that  leptin  production  is  also  regulated  by  factors  
other  than  adipose  tissue mass54.   
Factors  affecting  plasma  leptin  level: 
Leptin  level  mainly  depends  on  the  timing  of  meals.  Fasting  and  
eating  are  associated  with  decrease  and an  increase  in  the  plasma  
leptin  levels  respectively. It is  increased  by  emotional  stress49.   
Leptin  level  is decreased  when  testosterone  level  is  increased  
whereas  its  level  increases  along  with  the  increase  in  estrogen.  It  is  
chronically  reduced  by  physical exercise  training54,55. 
Mechanism  of  action:   
Leptin  signals  through  six  splice  variants  of   membrane  receptors 
known  as  Ob – Ra  to  Ob – Rf.  It  is  also  named  as  LepRa  to  
LepRf. Among  them  most  common  is  long  form  Ob – Rb.  They  
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belong  to cytokine  receptor   superfamily10,47.  All  of  them  have  an  
extracellular  binding domain  and  an  intracellular  tail.  These  receptors  
are  encoded  by  a  single gene,  called  LEPR.   
Leptin  crosses  the  blood  brain  barrier  through  a  saturable   active  
transport  system  and  binds  with  its  receptor13.  Binding  of  leptin  to  
its membrane  receptor  results  in  homodimerization.  It  activates  many  
intracellular  enzyme  cascades  involve  Janus  kinase  ( JAK )  and  
signal  transducer  and  activator  of  transcription  ( STAT)  pathways10.  
The  STAT proteins  then   migrates  to  the  nucleus  and  activates  
leptin  target  genes. The  long  form  leptin  receptor  is  required  for  
normal  energy  homeostasis. 
Leptin  receptors  are  highly  expressed  by  several  hypothalamic  
nuclei  including  arcuate ,  dorsomedial,  ventromedial,  ventral  
premamillary nuclei10.  The  extrahypothalamic  sites  include  Nucleus  
tractus  solitarius, substantia  Nigra,  ventral  tegmental  area,  para  
brachial  and  dorsal  raphe  nucleus56.  
Leptin  signalling  is  required  for  normal  energy  balance.  Humans  
and  animals  lacking  leptin  or  leptin  receptor  have  severe  
hyperphagia  and obesity.   It  causes  lipid  accumulation  in  many  
tissues  and  cellular  damage  which  is  called  lipotoxicity.  Leptin  gene  
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expression  is  regulated  by  food  intake,  insulin,  growth  hormone, 
sympathetic  system,  steroids,  thyroid  hormone,  poly  unsaturated  fatty 
acids,  retinoic  acid  and  leptin  itself57.  Any  homozygous  frameshift ,  
nonsense,  missense  mutations  in  this  leptin  gene ( LEP ) lead on to 
congenital  leptin  deficiency.  
Patients  with  congenital  leptin   deficiency  have  normal   
neurobehavioural  development  and  no  dysmorphic   features.  They  
will  have  normal   birth  weight  but  show  rapid  weight  gain  there  
after  resulting  in  severe  obesity.  Other  features  include type  2  
diabetes  mellitus,  abnormalities  in  sympathetic  nerve  function, 
hypothalamic  hypothyroidism,  hypogonadotropic  hypogonadism,  
delayed onset  of  puberty,  decreased  T  cell  count  and  function  
resulting  in  increased  infection  in  childhood.  The  condition  is  
diagnosed  on  the  basis  of undetectable  serum  leptin  measurement  
followed  by  genotyping  of  LEP gene52.  
Upto  3%  of  patients  with  severe  obesity  will  have  loss  of  
functional  gene  mutation  encoding  leptin  receptor  ( LEPR ).  This  is 
measured  by  an  inability  of  leptin  to  phosphorylate   STAT3  proteins  
in invitro  studies.  Clinical  phenotype  is  similar  to  leptin  deficiency.  
Serum levels  are  not  elevated  disproportionately.  Only  in  particular  
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types  in which  the  mutation  affects  the  transmembrane  domain  
results  in  truncated extracellular  domain  that  may  act  as  a  false  
binding  protein  leads  to abnormally  elevated  leptin  levels52. 
Patients  can  be  treated  with  r- Leptin  as  daily  subcutaneous 
injections47.  It  improves  insulin  sensitivity  and  leads  to  decrease  in  
fasting glucose.  Hypertriglyceridemia  refractory  to  traditional  lipid  
lowering  agents  shows  best  response  to  leptin  replacement.  An  
analogue  of  human  leptin,  Metreleptin  is  under  investigation  for  the  
treatment  of  diabetes,  hypertriglyceridemia  and  rare  forms  of  
lipodystrophy  with  severe  metabolic  abnormalities. 
In  children  r- leptin  therapy  reduces  food  intake  and  body  weight 
with  no  effects  on  energy  expenditure  and  fat  oxidation.  In  adults  
it affects  the  food  intake  as  well  as  energy  expenditure.  It  is  
observed  as weight  loss  and  increase  in  fat  oxidation  by  more  than  
3  times  in  24 hours52.  Large  and  frequent  doses  are  needed  because  
of  leptin’s  low circulating  half   life,  low  potency  and  poor  
solubility. 
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Functions  of  leptin: 
1. Role  in  enegy  expenditure: 
It  is  a  potent  appetite  suppressor  and  primary  regulator  of  energy  
expenditure.  The  critical  physiological  role  of  leptin  appears  to  be,  
signalling  caloric  deficiency  and  thus  mediate  the  appropriate  
metabolic  changes rather  than   signalling  caloric  excess49.  It  
maintains  minimum  level  of  energy stores  during  periods  of  caloric  
restriction.   
So  whenever  the  energy  stores  become  insufficient,   leptin  
concentrations  become  very  low,  commanding  the  body  to  seek  
food  and  become  thrifty.  Thus  leptin  acts  as  a bidirectional  signal  
that  switches  physiologic  regulation  between  fed  and  starved  
states56.  Lack  of  leptin  is responsible  for  multiple  neuroendocrine  
abnormalities  caused  by  starvation. 
Leptin  controls  appetite  by  acting  on  hypothalamic  arcuate   and 
paraventricular  nuclei.  A  complex  network  of  neuropeptides  are  
involved  in  signals  regulating  appetite   and  hunger  in  hypothalamus.  
These  include catabolic  POMC  ( pro opio melanocortin ),  anabolic  
neuropeptide  Y / agouti – related protein  ( NPY / AgRP ).  POMC  
produces  a  number  of  peptides, including  α  MSH ( melanocyte  
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stimulating  hormone )  to  suppress  appetite whereas  both  NPY / AgRP  
are  orexigenic  ( appetite inducing )  peptides10. 
Leptin   directly  depolarizes  POMC  neurons  thus  activating  them  to 
suppress  appetite.  It  also  inhibits  NPY / AgRP  neurons  by  
hyperpolarising them10.  Deletion  of  leptin  receptors  selectively  in  
POMC  neurons  produces obesity.  Until  now  leptin  to  arcuate  
pathway  represents  the  best characterised  pathway  involved  in  the  
regulation  of  body  weight52. 
Leptin  has  satiety  inducing  effects  by  suppressing  orexigenic signals.  
It  disrupts  potential  feedback  mechanism  between  body weight  
changes  and  plasma  ghrelin  in  lean  adult  rats36.  
2. Role  in  metabolism: 
Leptin  affects  metabolism  by  stimulating  fatty  acid  oxidation  and  by  
decreasing  lipogenesis.  It  has  an  important  role  in   liporegulation  of  
peripheral  tissues.  It  protects  peripheral  tissues  like  liver,  skeletal  
muscle, cardiac  muscle,  β  cells  from  more  lipid  accumulation  by  
directing  excess  calories  into  adipose  tissue  for  storage.  This  action  
of  leptin  contributes  to  the  maintenance  of  insulin  sensitivity  in  
peripheral  tissues46.  
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Leptin  activates  AMPK  ( Adenosine  monophosphate  kinase )  in 
muscle  and  liver10.  As  a  consequence  of  AMPK  activation,  ATP  
consuming anabolic  pathways  are  inhibited,  whereas  ATP  producing  
catabolic pathways  are  activated.  Activated  mechanisms  include  
glucose  transport,  β  oxidation,  glycolysis  and  mitochondrial  
biogenesis52. 
3. Circulatory  system: 
Leptin  modulates  T  cell  activity  in  immune  system58.  It  increases  
the immune  response  to  atherosclerosis  in  obesity.  Exogenous  leptin  
promotes angiogenesis  by  increasing  vascular  endothelial  growth  
factor  levels. It  also  increases  platelet  aggregation.  Leptin  maintains  
sufficient  energy stores  to  enhance  erythropoiesis,  lymphopoiesis  and  
myelopoiesis.  
4. Lung  surfactant  activity: 
In  fetal  lung  leptin  is  secreted  from  mesenchyme  under  moderate 
stretch.  Leptin  acts  on  the  receptors  in  alveolar  type  II  epithelium  
and  induces  surfactant  expression59. 
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5. Reproduction: 
In  mice  leptin  is  required  for  both  male  and  female  fertility.  In  
humans,  the  effect  is  minimal.  In  females  the  ovulatory  cycles  are  
linked  to  energy  balance  and  if  this  is  highly  negative  then  the  
cycle  stops,  the  women  stops  menstruating.  Leptin  levels  outside  an  
ideal  range  have  a  negative  effect  on  egg  quality  and  outcome  
during  in  vitro  fertilization.  It  also  has  a  role  in  polycystic  ovary  
syndrome60.  The  mechanism  yet  to  be identified. 
Leptin  is  also  produced  by  placenta.  So  its  level  rises  during 
pregnancy  and  falls  after  parturition.  Leptin  is  also  expressed  in  
fetal  membranes  and  uterine  tissue.  Uterine  contractions  are  
inhibited  by  leptin. It   plays  a  role  in  hyperemesis  gravidorum. 
6. Bone  metabolism: 
Leptin  acts  via  β2  adrenergic  receptors  in  osteoblasts  and  inhibits  
its  proliferation.  Additionally  it  favours  bone  resorption  by  
increasing  osteoblastic  expression  of  RANKL.  Leptin  affects  bone  
metabolism  via direct  signalling  from  the  brain.  It  acts  to  reduce  
cancellous  bone  and conversely  increases  cortical  bone52. 
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7. Brain: 
fMRI  studies  in  humans  confirm  that  leptin  mediates  its  adipostatic  
effect  through  hypothalamic  and  other  brain  areas  that  are  important  
in emotional  and  cognitive  control.  Fulton  and  colleagues  
demonstrated  that  leptin  also  affects  brain  self  stimulation  
suggesting  that  leptin  has  the ability  to  affect  CNS circuits  
classically  involved  in  Reward56.  Low circulating  plasma  leptin  
levels  has  been  associated  with  anorexia, depression,  HIV and  the  
development  of  Alzheimer’s  disease. 
8. Inflammatory  marker: 
The  structure  and  function  of  leptin  resembles  Interleukin  6  ( IL 6 )  
and  is  a  member  of  cytokine  superfamily  which  will  take  part  in  
chronic inflammation12. It  also  induces  the  production  of  various  
cytokines,  including  IL 658. Circulating  leptin  seems  to  affect  
Hypothalamo  Pituitary Adrenal  axis,  suggesting  a  role  for  leptin  in  
stress  response.  Chronically elevated  leptin  concentrations  are  
associated  with  increased  white  blood  cell  counts,  obesity,  
overeating  and  inflammation  related  diseases  including  hypertension,  
metabolic  syndrome,  cardiovascular  disease7. 
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9. Obesity  and  Lepitn: 
In  obese  individuals  there  is  usually  a  high  circulating  concentration  
of   leptin.  These  people  are  said  to  be  resistant  to  the  effects  of  
leptin,  in  much  the  same  way  that  people  with  type  2  diabetes  are  
resistant  to the  effects  of  insulin.  The  sustained  high  concentrations  
of  leptin  from  the  enlarged  adipose  stores  implies  leptin  
desensitization. 
Leptin  resistance  acts  as  a  metabolic  disorder  that  contributes  to  
obesity.  This  is  because  the  major  physiological  role  of  leptin  is  
suggested  to  be  not  as  a  satiety  signal  to  prevent  obesity  in  times  
of  energy  excess,  but  as  a  starvation  signal  to  maintain  adequate  
fat  stores  for  survival  during  times  of  energy  deficit.  So  leptin  
resistance  in overweight  individuals  is  the  standard  feature  of  
mammalian  physiology,  which  confers  a  survival  advantage.  
Leptin  and   hypertension: 
Leptin  is  a  pleotropic  hormone  with  multiple  actions  that  are 
potentially  relevant  not  only  to  the  control  of  feeding  but  also  to 
several  systemic  and  metabolic  functions.  Several  studies  have 
reported  that  strong  correlation  exists  between  high  plasma  leptin 
levels  and  development  of  hypertension. 
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Leptin  deficient  ob / ob  mice  have  lower  blood  pressure  than  lean  
controls  despite  severe  obesity  and  leptin  administration  to these  
mice  increases  their  blood  pressure  up  to  the  level observed  in  lean  
controls61.  It  shows  that  apart  from  obesity,  other  mechanisms also  
exists  via  which  leptin  causes  hypertension. 
In  vivo  studies  proved  that  leptin  causes  widespread 
sympathoactivation  of  metabolically  active  tissues10.  In  
concentrations higher  than  the  physiological  level  it  exerts  adverse  
effects  on  the vasculature  by  peripheral  actions  include,  stimulation  
of  reactive oxygen  species,  impaired  NO  production,  renal  sodium  
retention, increased  endothelin  1  synthesis,  transactivation  of  
epidermal  growth factor  receptor  and  inhibition  of  angiogenesis  
resulting  in  blood  pressure  elevation14,62. 
By  interacting  with  diverse  mediators  and  regulators,  leptin 
stimulates  autonomic  nervous  system  activity.  Animal  studies  
showed  that,  transgenic  mice  with  leptin  over  expression  had  higher 
blood  pressure  as  compared  with  control  animals  and  the 
hypertension  was  reversed  by  sympathetic  ganglionic  blockade9.  
Immediately  after  leptin  administration  sympathetic  discharge  to 
brown  adipose  tissue,  kidneys,  adrenal  glands  and  hind  limbs 
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increases  in  rats  whereas  chronic  administration  shifts  the  pressure 
natriuresis  curve  to  the  right  by  increasing  the  renal  tubular  sodium 
reabsorption10,61. 
Other  possible  mechanisms  include  increased  expression  of adipose  
tissue  derived  hormone  Angiotensin  II,  increased  plasma renin  
activity,  higher  plasma  levels of  adrenalin  and  noradrenalin50, 
increased  corticotrophin  releasing  factor  from  brain.  
Obese  humans  are  resistant  to  anorexic  and  thermogenic actions  of  
leptin  but  their  sympatho- excitatory  and  pressor  actions of  leptin  
appears  to  be  preserved  in  these  subjects.  In  animals  when  
compared  to  normal  rats,  spontaneously  hypertensive  rats  and obese  
rats  are  refractory  to  natriuretic  effects of  leptin.   
Several  mechanisms  have  been  postulated  for  this  selective leptin  
resistance.  Saturation  in  the  transport  of   leptin  in  to  the central  
nervous  system  represents  one  potential  mechanism  of  leptin 
resistance  in  obesity10.  Studies  have  shown  that  decreased  CSF 
concentration  of  leptin  in  obese  people13.  Also  it  involves  alteration  
in  intracellular  leptin  signalling  pathways  in  the  hypothalamus.  
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The  ability  of  leptin  to  stimulate  JAK / STAT  pathway  is impaired  
by  activating  the  suppressors  of  the  cytokine   signalling family  
(SOCS-3).  This  SOCS-3  protein  acts  intracellularly  to  inhibit STAT  
phosphorylation   induced  by  the  leptin  receptor.  Protein tyrosine  
phosphatase  1b  ( PTP 1b )  also  inhibits  intracellular  leptin signalling.  
Defects  in  leptin  receptor  can  lead  to  leptin  resistance, but  this  is  
rare  in  humans10.  
Persistent  high  levels  of  leptin  causes  hypertension,  insulin 
resistance36,48,53  and  stimulates  vascular  smooth  muscle  cell  
proliferation62, accelerates  vascular  calcification,  induces  oxidative  
stress  in endothelial  cells53,  that  contributes  to  atherogenesis,  platelet 
adhesiveness  thereby  increasing  the  cardiovascular  risk50,58.  
Studies  related to  serum  leptin  and  blood  pressure: 
Freddy  Contreras  et  al  in  their  study,   have  found  out  high  serum  
leptin  levels  in  hypertensive  subjects.  They  have  concluded  that,  
leptin  increases  the  blood  pressure  by  activating  the  sympathetic  
nervous  system.  Leptin  is  also  involved  in  the  atherogenic  process  
by  encouraging  platelet  aggregation  and  thrombosis  and  also  
inflammatory  cytokine  production  which  contributes  to  insulin  
resistance  and  endothelial  malfunction63. 
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F. Galletti  et  al  in  their  study,  proved  that  higher  plasma leptin  
levels  in  normotensive  adult  male  individuals  are  associated  with 
increased  risk  of  developing  hypertension  independently  of  several 
potential  confounders.  They  have  also  confirmed  that  there  is  a  
strong association  between  BMI  and  plasma  leptin  concentration61.  
Kawaljit  Kaur  Khokhar  et  al  in  their  clinical  study, confirmed  that  
both  normal  and  obese  hypertensive  premenopausal  and post  
menopausal  women  had  significantly  higher  serum  leptin  levels  than  
their  normotensive  counterparts.  The  results  revealed  that  there  was  
significant  influence  of  systolic  blood  pressure  on  serum  leptin  
levels.  And  also  it  was  significantly  higher  in  both  pre  menopausal   
and  post menopausal  obese  women  than  that  of   subjects  with  
normal  weight16.  
Muayad  S  Rahma  et  al  found   a  positive   correlation  between  
systolic  and   diastolic  blood  pressure  and  leptin  level64.   
Duanduan   Ma  et  al  from  their  National  Heart,  Lung,  and Blood  
Institute  Family  Heart  Study,  had  found  a  significant  association 
between  plasma  leptin  levels  and  hypertension  in  women.  And  also 
Plasma  leptin  levels  are  correlated  with  SBP  and  DBP  in  women. 
However,  after  adjusted  by  BMI,  the  correlation  appreciably  
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diminished,  suggesting  that  the  relationship  between  plasma  leptin  
levels  and  blood  pressure  was   mediated  by  BMI.  No  significant 
association  was  detected  in  men  in  their  study65. 
In  contrast  Almeida – pititto  et  al  in  their  study  done  on  non  
diabetic  Japanese  – Brazilian  women,  have  detected  that  there  is  no  
correlation   between  blood  pressure  and  plasma  leptin  levels40. 
Keiko  Wada  et  al  in  their  study  in  Japanese  men,  showed  that  
there  exists  a  highly  significant  positive  correlation   between  leptin  
levels and  blood  pressure,  BMI  and  age.  Leptin  was  positively  
related  with diastolic  blood  pressure  among  the  subjects  in  the  
normal  blood pressure  range  but  not  with  subjects  having  
hypertension66.  
Studies  related  to  serum  leptin  level  and  BMI: 
FB  Hu  et  al  in  their  study  done  in  rural  Chinese  population, have  
found  that  there  was  a  significant  correlation  between  leptin  
concentration  and  diastolic  blood  pressure  but  not  the   systolic  
blood  pressure.  Females  had  much  higher  leptin  levels  than  males.  
Leptin  levels  in  their  study  strongly  correlated  with  BMI  and  waist  
hip  ratio67. 
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Waleed  S.  Mohamed  et  al  in  their  study,  found  that  plasma leptin  
level  showed  a  significant  positive  correlation  with  BMI,  waist 
circumference,  systolic  blood  pressure   and  diastolic  blood  pressure  
in obese  individuals  and  patients  with  metabolic  syndrome36. 
In  a  cross  sectional  study  done  by  Costas  Thomopoulos  et  al  found  
that  masked  hypertension  was  associated  with  increased  plasma  
leptin  and  decreased  leptin  receptor  levels  independent  of  
confounders  like  body  size  and  metabolic  parameters.  They  have  
also demonstrated   that  the  healthy  offspring  of  hypertensive  patients  
are  characterized  by  hyperleptinemia.  So  they  have  suggested  that  
hyperleptinemia  may  precede  and  contribute  to  the  development  of  
hypertension  rather  than  secondary  to  increased  blood  pressure14. 
Anoop  Shankar  and  Jie  Xiao  et  al  observed   a  positive association  
between  plasma  leptin  levels  and  hypertension  in  both  age and  sex  
adjusted  model  and  the  multivariable  adjusted  model.  This 
association  was  seen  both  in  normal  weight  and  overweight / obese 
subjects.  Their  another  important  finding  was,  that  the  average  
plasma  leptin  levels  were  3  times  higher  among  women  compared  
with  men15.            
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Gianvincenzo  Barba  et  al  had  observed  that  leptin  could have  a  
prohypertensive  effect.  Plasma  leptin  levels  were  significantly and  
directly  associated  with  blood  pressure  and  BMI. The  association  
still  apparent  when  only  normotensive  subjects  were  considered 
independently  of  age  and  BMI.  Elevated  plasma  leptin  levels  also 
associated  with  higher  systolic  and  diastolic  blood  pressure68.  
Takuya  Imatoh  et  al  who  performed  conditional  logistic  regression  
analysis  to  analyze  the  association  between  serum  leptin  levels  and  
hypertension,  found  that  the  subjects  in  the  highest  quartile  of  
serum  leptin  levels  had  a  significantly  increased  risk  of  
hypertension  compared  with  those  in  lowest  quartile.  They  have  
also  suggested  that  increased  fasting  plasma  leptin  levels  appear  to  
be  related  to  various  cardiovascular  diseases  including  stroke  and  
Myocardial  infarction.  Leptin  thus  seems  to  play  an  important  role  
in  development  of  cardiovascular  diseases69.  
Anne  E.  Sumner  et  al  in  their  study,  established  that  leptin  highly  
correlates  with  body  fat  mass.  They  also  described  a  significant 
gender  difference  in  leptin  concentration,  but  there  was  no  
significant difference  in  leptin  levels  between  pre  and  post  
menopausal  women. They  have  also  observed  that  there  is  no  
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relationship  between  leptin concentration  and  age.  In  conclusion  
leptin  concentration  in  African Americans  is  determined  by  fat  mass  
and  gender70.   
Body  mass  index  and  waist  circumference were  strongly  positively  
correlated  with  leptin  concentration  in  men  and women in Paul  
Zimmet  et  al  cross  sectional  study.  Waist  to  hip  ratio  was  less  
strongly  correlated  with  leptin concentration.  Concentrations  were  
higher  in  women  than  in  men,  even at  the  same  body  mass  index  
or  waist  circumference71.  
Mikolaj  Winnicki  et  al  in  their  study  observed  a  strong independent  
association  between  leptin  levels  and  BMI.  A  Minocci  and his  
colleagues  had  observed  that  leptin  concentrations  were  significantly  
and  directly  related  to  BMI  and  inversely  correlated  with waist  hip  
ratio  in  a  single  regression  model.  In  multiple  regression analysis  
WHR  remained  independently  associated  to  leptin concentrations72. 
Rungsunn  Tungtrongchitr  et  al  found   higher  leptin  concentration  in  
overweight  and  obese  subjects  in Thai  when  compared  with  normal   
subjects.  The  medians  of  leptin  were  significantly  higher  in  
overweight  and  obese  males  than  females73.  
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San  Antonio  heart  study  which  is  a  population  based  study,  there  is  
a  significant  gender  difference  in  serum  leptin  levels  after  
adjustment  for  BMI.  According  to  them,  the  possible  reason  for  the  
gender  difference  in  leptin  levels  may  be   the  differences  in  fat  
depots  between men  and  women.  Men  have  lower  levels  of  overall  
adiposity  but  greater  visceral  adiposity  than  women74.   
Studies  related  to  gender  differences  in  serum  leptin  level:  
Lonnqvist  et  al  have  shown  that  subcutaneous  fat  produces  more  
leptin  mRNA  than  visceral  fat. This  could  explain  why  women  have  
more  leptin  levels,  as  they  have  more  subcutaneous  fat  than  
visceral  fat13. 
In  another  study  done  by Constance  E  Ruhl  and  James  E  Everhart ,  
women  of  all  ethnic  groups had  substantially  higher  fasting  serum  
leptin  concentrations  than  men. Leptin  concentrations  were  strongly  
correlated  with  various  anthropometric  measures  in  women  and  
men,  both  in  the  univariate analysis  and  when  age  and  ethnicity  
were  controlled  for.  This  study revealed  that,  leptin  concentrations  
were  associated  with  both  waist  and  hip  circumferences,  
circumference  ratios  and  with  skin  fold  thicknesses,  independent  of  
BMI75.   
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Kwang  Kon  Koh  et  al  had  analyzed  the  results  from  clinical 
surveys   on  leptin  interaction  with  cardiovascular  diseases  and  
observed  that  the  plasma  leptin  is  higher  in  male  patients  who  
subsequently develop  first  ever  myocardial  infarction  than  in  control  
subjects.  They  have  concluded  that  leptin  is  predictor  of  myocardial  
infarction, coronary  events  and  stroke  independent  of  body  mass  
index47.  
S. Soederberg  et  al  in  their  nested  case  referent  study  had  observed 
that  high  levels  of  leptin  were  associated   with  high  BMI,  high  
systolic  and  diastolic  blood  pressure.  They  said  that,  circulating  
levels of  leptin  were  found  to  be  significantly  associated  with  
established  cardiovascular  risk  factors  such  as  elevated  blood  
pressure  and  obesity.  From  their  two  subsequent  studies,  they  have  
concluded  that  plasma  leptin  strongly  predicts  first -  ever  AMI          
( Acute  Myocardial  infarction )  and  also  first – ever  haemorrhagic  
stroke 76.  
Martins  and  his  colleagues  had  observed  a  strong  correlation 
between  BMI  and  serum  leptin  levels.  In  their  study  serum  leptin 
levels  in  females  were  three  times  higher  than  in  males.  They  have 
concluded  that  obesity  defined  by  BMI  was  the  strongest  predictor  
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of  high  leptin  levels  and  serum  leptin  could  be  considered  as  an  
additional component  of  metabolic  syndrome  and  a  new  
cardiovascular  risk  factor77.  
In  their  study  done  in  newborn  babies,  Samsad  Jahan  and   his  
colleagues  found  a   significant  difference  in  plasma  leptin  levels  
between  male  and  female  babies.  The  gender  dimorphism  in  leptin  
production  observed  very early  in  life  indicates  the  genetic  
difference  in  leptin   production78.   
Hence  leptin , which  is  an  important  factor  in  controlling  food 
consumption   and  energy  expenditure  may  have  a  role  in  
development of  hypertension  through  its  various  peripheral  actions. 
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MATERIALS  AND  METHODOLOGY 
Design  of  the  study: 
It  is  a  cross  sectional  type  of  study. 
Place  of  the  study: 
The  study  was  conducted  in  Coimbatore  Medical  College  and  
Hospital,  Coimbatore. 
Collaborating  Departments: 
Department  of  Medicine  and  Department  of  Biochemistry, 
Coimbatore  medical  college  and  Hospital,  Coimbatore. 
Period  of  study: 
August  2013  to  March   2014. 
Study  subjects: 
A  total  of  90  subjects  of  age  group  35  –  75  years  were  included  
in  the  study.  Study  group  comprised  of  48  subjects  which  include  
26 males  and  22  females  with  hypertension. They   were  selected  
from  the  hypertension  outpatient  department  of  Coimbatore  medical  
college  and  hospital,  Coimbatore. 
Apparently  42  healthy  individuals  comprising  of   22  males  and  20  
females  with  normal  blood  pressure  were  taken  as  control  group. 
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Inclusion  criteria: 
Individuals  having  essential  hypertension  in  the  age  group  between  
35 - 75  years  were  included  in  the  study  and   age matched  
normotensive  individuals  were  included  as  control  group in  the  
study. 
Exclusion  criteria: 
Individuals  having  Diabetes  mellitus  and  any  other  medical disorders  
that  predisposes  to  secondary  hypertension  like  renal problems,  
endocrine  abnormalities,  liver  diseases,  any  chronic illnesses  and   
their  complications  were  excluded  from  the  study. 
Materials  used  for  the  study: 
1. Proforma:  To  obtain  detailed  history,  to  record  the  vital 
parameters  and  to  measure  the  anthropometric  indices. 
2. Portable  weighing  machine:  To  record  the  body  weight  in 
kilograms.  
3. Stadiometer:  To  measure  the  standing  height  in  centimetres. 
4. Non  elastic  inch  tape:  To  measure  the  waist  and  hip  size in  
centimetres. 
5. Standardized  mercury  sphygmomanometer:  To  record  the blood  
pressure. 
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6. Euro  immuno  analyzer  -  To  estimate  serum  leptin  levels. 
Methodology: 
The  study  was  initiated  with  the  approval  of  institutional ethical  
committee.  The  study  was  carried  out  after  explaining the  
procedures  in  detail  and  getting  written  informed  consent from  all  
the  subjects.  
The  experimental  protocol  involved  are, 
1. Recording  of  a  detailed  history  including  family  history  to 
rule  out  Diabetes  mellitus  and  history  of   Renal,  liver diseases  
to  rule  out  the  causes  of  secondary  hypertension. 
2. Measurements  of  anthropometric  indices: 
The  subjects  were  asked  to  stand  erect  with  their  arms relaxed  
by  their  side  and  with  feet  together  without  shoes. By  using  a  
portable  standard  weighing  machine,  weight  in kilogram  was  
recorded.  
By  using  a  stadiometer ,  height  in  centimetres  was measured  
by  asking  the  subject  to  stand  erect  without  shoes  and  the  
vertical  height  was  measured.  
Body  mass  index  was  calculated  using  the  Quetelet’s index, 
                     BMI  =  weight  ( Kg )  /  height  in  meters2 
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3. Measurement   of  Waist  circumference: 
Waist  circumference  was  measured  using  an  inch  tape  at the  
level  of  midpoint  between  the  lower  rib  margin  and  the  iliac  
crest  at  the  end  of  normal  expiration  with  the subject  in  
standing  position.  
4. Measurement  of  hip  circumference: 
Hip  circumference  was  measured  at  the  level  of  greater 
trochanter. 
5. Measurement  of  blood  pressure: 
First  the  subjects  were  asked  to  sit  with  arm  and  back 
supported  and  the  legs  uncrossed  in  an  armed  chair  for  15  
minutes  in  a  quiet  room  with  comfortable  room  temperature.  
Then  blood  pressure  was  recorded  in  all  subjects  using  a  
standard  sphygmomanometer  having  a  cuff size  of  25  x  12.5  
centimetres.   The  mercury  manometer  was placed  at  his  /  her  
heart  level.  Then  the  blood  pressure  was  recorded  first  by  
palpatory  method  and  then  by auscultatory  method.  After  10  
minutes  again  blood  pressure was  recorded  for  the  same  
individual  by  the  same  2  methods.  Mean  value  was  taken  for  
analysis.  
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6. Blood  investigations: 
Blood  sample  was  collected  after  overnight  fasting.  Ante  
cubital  vein  of  the  forearm  was  selected  for  venous blood  
collection.  The  skin  over  the  vein  was  sterilized  with spirit  
cotton  swab.  A  disposable  5  ml  syringe  with  sterile needle  
was  introduced  in  to  the  vein  and  the  required  amount   of  
blood  was  collected.  The  serum  was  separated by  centrifuging  
the  blood  to  3000  rpm  for  5  minutes.  
The  serum  was  used  to  estimate  leptin  level.  This was  done  
by  Enzyme  immuno  sorbent  assay  using  KAP 2281  Human  
leptin  ELISA  kit  ( diasource company ). 
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STATISTICAL TOOLS 
The  information  collected  regarding  all  the  selected  cases  were  
recorded  in  a  Master  Chart.  Data  analysis  was  done  with  the  help  
of computer  using Epidemiological  Information  Package             
(EPI 2010)  developed  by  Centre  for  Disease  Control,  Atlanta. 
 
Using  this  software  range,  frequencies,  percentages,  means,  standard 
deviations,  chi  square,  ‘t’  and   'p'  values  were  calculated. ‘t’  test  
was  used  to  test  the  significance  of  difference  between  quantitative  
variables  and  Yate’s  and  Fisher’s  chi  square  tests  for  qualitative  
variables.  A  'p'  value  less  than  0.05  is taken  to  denote  significant  
relationship. 
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RESULTS 
Table 1: Age  distribution  in  study  group  and  control  group 
Groups  Range in years Mean ± SD 
Study group 36-72 54.4±8.3 
Control group 35-72 51.3±9.4 
 
 
Table 2 : Gender  wise  distribution  between  the  study  group  and  
the  control  group 
Sex 
Study group Control group 
No % No % 
 Male 26 54.2 22 52.4 
 
Female 
22 45.8 20 47.6 
 
Age  and  gender  wise  distribution  is  same  in  both  the  study  and  the 
control  group. 
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Figure : 1 Age  distribution  in  study  group  and  control  group 
 
 
 
 
 
 
 
 
 
 
Figure  2 : Gender  distribution  between  study  group  and  control 
group 
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Table 3 : Comparison  of   Blood  pressure  between  the  study  
group  and the  control  group 
Group 
Systolic blood 
pressure 
Diastolic blood 
pressure 
Mean ±  SD Mean ±  SD 
Study group 158.1 ±  23.6          95.9 ± 9.6 
Control group 113.3 ± 8.49          73.8 ± 7.0 
‘p’ < 0.0001 significant < 0.0001 Significant 
Both  the  systolic  and  diastolic  blood  pressure  are  high  in  cases  
when compared  to  controls  and  the  difference  is  statistically  
significant.  
 
Figure 3 : Comparison  of   Blood  pressure  between  study  group  
and control  group 
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Table 4 : Comparison  of  serum  leptin  levels  between  the  study  
group (hypertensive  patients)  and  the  control  group  
(normotensive  persons) 
Groups 
Blood pressure 
(mm/Hg) 
Serum leptin levels 
(ng/ml) 
Mean ± SD Mean ± SD 
Study group 158.1 ±  23.6 / 95.9 ± 9.6  8.15 ± 2.68 
Control group 113.3 ± 8.49 / 73.8 ± 7.0 1.74 ± 1.04 
P< 0.0001 significant 
Serum  leptin  levels  are  increased  in  the  study  group  when  
compared  to control  group  and  the  difference  is  statistically  
significant. 
 
Figure   4 : Comparison  of  serum leptin  levels  in  hypertensive  
patients (study group)  and  normotensive  persons  ( control  group ) 
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Table : 5  Comparison  of  systolic  blood  pressure  and  serum  
leptin  levels 
Groups  
Systolic  blood 
pressure (mm/Hg) 
Serum leptin levels 
(ng/ml) 
Mean ± SD Mean ± SD 
Study group 161.0 ± 23.9 8.15 ± 2.68٭ 
Control group 138.3 ± 4.1 1.74 ± 1.04 
P < 0.0268 Significant 
Increase  in  systolic  pressure  is  associated  with  an  increase  in  serum  
leptin  levels  and  the  difference  is  statistically  significant. 
 
Figure 5 : Comparison  of  systolic  blood  pressure  and  serum  
leptin  levels 
 
 
  8.15
1.74
100
110
120
130
140
150
160
170
180
0 2 4 6 8 10
SB
P 
m
m
/H
g
leptin levels (ng/ml)
79 
 
Table : 6  Comparison  of  Diastolic  blood  pressure  and  serum  
leptin levels 
Groups  
Diastolic  blood 
pressure (mm/Hg)           
Leptin levels (ng/ml) 
Mean ± SD Mean ± SD 
Study group 96.6 ± 9.5  8.15 ± 2.68٭ 
Control group 91 ± 8.8 1.74 ± 1.04 
P value  = 0.1804 Not Significant 
Increase  in  diastolic  pressure  is  associated  with  an  increase  in  
serum leptin  levels  and  the  difference  is  not  statistically  significant. 
 
Figure 6: Comparison of  Diastolic  blood  pressure and  leptin levels 
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Table : 7  Gender  differences  in  serum  leptin  levels  in  the  study  
group 
Gender 
Number of 
hypertensive 
patients 
Serum leptin levels 
(ng/ml) 
Mean ± SD 
Males  26 7.81 ± 2.3 
Females  22 8.44 ± 2.97 
P= 0.4226  not significant 
There  is  no  statistically  significant  gender  difference  in  serum  leptin  
levels  in  the  study  group. 
 
Figure 7: Gender differences in  serum  leptin  levels  in  study  group 
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Table : 8 Comparison  of  age  and  serum  leptin  levels  in  the study 
group 
Groups  
Number of 
hypertensive  
patients 
Serum leptin levels 
(ng/ml) 
         Mean ± SD 
Up to 40 years 1 5.5 
41- 50 years 16 6.95 ± 1.96 
51 – 60 years 23 8.77 ± 2.91 
Above 60 years 8 9.11 ± 2.58 
P< 0. 0001 significant  
There  is  an  increase  in  serum  leptin  levels  as  the  age  advances  and  
the difference  is  statistically  significant. 
 
Figure 8: Comparison of age and serum leptin levels  in  study  group 
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Table :9  Comparison  of  serum  leptin  levels  and  BMI  in  the  
study group 
Groups 
according to 
BMI 
Number of 
hypertensive 
patients 
BMI Serum leptin levels (ng/ml) 
Mean ± SD Mean ± SD 
Normal BMI 
(19 – 25) 
10 27.16 ± 1.61 5.43 ± 1.59 
Overweight 
(26- 30) 
26 29.41± 2.62 6.82 ± 2.52 
Obese 
( >30) 
12 31.81 ± 1.43 8.63 ± 2.58 
P <0.0467 significant 
Increase  in  BMI  is  associated  with  an  increase  in  serum  leptin  
level  and the  difference  is  statistically  significant. 
 
Figure 9: Comparison of serum leptin levels and  BMI in study group 
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Table : 10  Comparison  of   Waist/ Hip  ratio  and  serum  leptin  
levels  in the  study  group 
Groups 
according to 
Waist Hip 
ratio 
Number of 
hypertensive 
patients 
 
Waist /Hip 
ratio 
Serum leptin 
levels (ng/ml) 
Mean ± SD Mean ± SD 
0.85 – 0.90 12 0.88 ± 0.01 6.58 ± 2.20 
0.91- 0.95 21 0.93 ± 0.01 7.06 ± 2.29 
0.96 – 1.0 15 0.97 ± 0.01 8.33 ± 3.58 
P<0.0001  significant 
Increase  in  waist  hip  ratio  is  associated  with  an  elevated  serum  
leptin level  and  this  association  is  statistically  significant. 
 
Figure  : 10  Comparison  of  Waist/ Hip  ratio  and  serum  leptin  
levels  in  study  group 
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Table :11  Comparison  of  Waist / Height  ratio  and  serum  leptin 
levels  in  the  study  group 
Groups 
according to 
Waist Height 
ratio 
Number of 
hypertensive 
patients 
Waist / Height 
ratio 
Serum leptin 
levels (ng/ml) 
Mean ± SD Mean ± SD 
0.5 22 0.52 ± 0.02 6.33 ± 2.31 
>0.5 26 0.63 ± 0.02 8.64 ± 2.79٭ 
P <0.0001 significant 
Increase  in  waist  height  ratio  is  associated  with  elevated  serum  
leptin  level  and  this  association  is  statistically  significant. 
 
Figure 11:  Comparison  of  Waist / Height  ratio  and  serum  leptin  
levels 
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Table 12 : Comparison  of  duration  of  hypertension  and  serum  
leptin  levels  in  the  study  group 
Duration of 
hypertension 
(years) 
Number of 
hypertensive patients 
Serum leptin levels 
(ng/ml) 
1-10 28 5.67 ± 2.16 
11-20 20 8.33 ± 4.03٭ 
P <0.0329  significant 
Patients  having  long  duration  of  hypertension  have  increased  serum  
leptin  levels  when  compared  to  short  duration  hypertensive  patients.  
This  difference  is  statistically  significant. 
 
Figure 12: Comparison  of  duration  of  hypertension  and  serum  
leptin levels 
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 DISCUSSION 
This  present  cross  sectional  study  was  done  on  48  hypertensive  
patients  in  the  age  group  between  35  to  75  years  taken  as  study  
group  and  42  individuals  with  normal  blood  pressure  in  the  same  
age  group  taken  as  control  group.  They  were  classified  as  
hypertensive  and  normotensive  group  according  to  the  JNC  7  
criteria.  The  mean  blood  pressure  for  the  study  group  is  about   
158/ 96  mmHg  and  the  control  group  is  about  114/74  mm  Hg.  
In  this  study  high  serum  leptin  level  is  seen  in  hypertensive  
patients  when  compared  to  the  persons  with  normal  blood  pressure. 
And  also  there  is  statistically  significant  correlation   between  serum  
leptin  level  and  systolic   blood  pressure,  age,  BMI,  waist  hip  ratio  
and  waist  height  ratio  in  hypertensive  patients.  There  is  some  
difference  in  serum  leptin  levels  between  males  and  females,  but  
this  difference  is  not  statistically  significant.  
Similar  finding  was  observed  by  Anoop  Shankar   and  Jie  xiao  et  
al,  Costas  thomopoulos   et  al,  Kawaljit  Kaur  Khokhar   et  al,  F. 
Galletti  et  al,  Freddy  Contreras  et  al,  Gianvincenzo  Barba  et  al  and  
Takuya  Imatoh  et  al,  Muayad  S  Rahma  et  al,  Duanduan   Ma  et  al, 
Keiko  Wada  et  al,  FB  Hu  et al,  Waleed  S.  Mohamed  et  al,       
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Anne  E.  Sumner  et  al,  Mikolaj  Winnicki  et  al,  Rungsunn  
Tungtrongchitr  et  al,  S. Soederberg  et  al.    
In  most  of  the  previous  studies  they  have  concluded  that  leptin 
increases  the  blood  pressure  by  activating  the  sympathetic  nervous 
system.  Renal  sympathetic  stimulation  mediated  by  leptin  is  
followed by  increased  sodium  and  water  retention.  Stimulation  of  
renin  secretion  is  also  a  contributor  to  the  increase  in  blood  
pressure.  
The  mechanism  of  leptin  in  rising  the  blood   pressure   has  been 
substantiated  by  animal  experiments.  An  intracerebro  ventricular  
injection  of  leptin  increases  the  activity  of  both  lumbar  and  renal  
sympathetic   nerve   and  reduces  arterial  blood  flow  to  the  skeletal  
muscle64.   
In  another  study  done  in  rats,  acute  systemic  leptin  administration  
increases  the  sympathetic  nerve  discharge  to  brown  adipose  tissue,  
kidneys,  adrenal  glands  and  hind  limbs.  In  the  same  animal  model,  
hypertension  was  reversed  by  administration  of  α  adrenergic  or  
sympathetic  ganglionic  blockade.  Chronic  leptin  administration  shifts  
the  pressure  natriuresis  curve  to  the  right  thereby  increases  the  
sympathetic   nerve  activity  and  tubular  sodium  reabsorption61.           
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Leptin  also  correlates  positively  with  systolic  and  diastolic  blood  
pressure64,73.  This  association  between  blood  pressure  and  leptin  was  
independent  of  BMI  suggesting  that  leptin  is  a  physiological  
mediator  of  some  degree  of  diastolic  blood  pressure  elevation  in  
obesity66.  The  possible  mechanism  for  strong  association  between  
leptin  and  diastolic  blood  pressure  is  that,  leptin  activates  the  
sympathetic  system  which  leads  to  an  increase  in  peripheral  
resistance66.   
The  association  of  leptin  and  hypertension  was  independent  of 
traditional  factors  such  as  age,  sex,  smoking  and  alcohol  intake,  
BMI,  Diabetes  mellitus  and  serum  cholesterol47. 
F. Galletti  et  al  did  an  eight  year  follow  up  study  in  489  untreated 
normotensive  subjects  to  detect  whether  serum  leptin  levels  predict  
the development  of  hypertension.  At  the  end  of  follow  up  period,  
264  new  cases  of  hypertension  were  detected.  From  this  prospective  
study,  they  have  concluded  that,   higher  plasma  leptin  levels  in  
normotensive  adult  male  individuals  are  associated  with  an  increased  
risk  of  developing  hypertension  independently  of  several  potential  
confounders61.  So  circulating  leptin  acts  as  a  significant  predictor  of  
hypertension  development. 
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There  is  some  evidence  that   the  antihypertensive  medications  lower  
plasma  leptin  levels.  So  in  all  the  previous   studies  done  on  
hypertensive  patients  taking  medications,  there  is  a  possibility  that  
the observed  association  may  be  an  underestimation  of  true  
existence.  So  Anoop  Shankar  and  Jie  Xiao  et  al  have  also  done  a  
supplementary   analysis  to  exclude  subjects  with  antihypertensive  
medications,  even  then  the  association  between  leptin  and  
hypertension  was  similar.  So  they  have  concluded  that  plasma  leptin  
levels  may  serve  as  a  novel  adipose  tissue  derived  biomarker  for  
hypertension15.  
The  investigation  of  a  large  random  sample  of  untreated  male 
participants  of  the  Olivetti  heart  study  shows  a  graded , statistically 
significant  and  clinically  relevant  association  between  plasma  leptin 
concentration  and  blood  pressure.  It  is  largely  independent  of  body 
mass  and  abdominal  adiposity.  Elevated  levels  of  plasma  leptin  in  
the  presence  of  excess   central  adiposity  reflect  a  condition  called   
leptin  resistance,  characterized  by  the  inability  of  leptin  to  promote  
a  reduction  in  body  fat  accumulation.  In  that  study  it  was  not  
concluded     whether  resistance  to  the  physiological  effect  of  leptin  
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on  visceral  fat  is  matched  by  resistance  to  other  peripheral  effects  
of  this   hormone.  
These  results  contribute  to  the  understanding  of  the mechanistic  
pathways  linking  overweight  and  abdominal  adiposity  to high  blood  
pressure  and  are  relevant  to  the  prevention  of  the cardiovascular  
complications  of  this  epidemic  metabolic  alteration73.    
Leptin  and  its  association with  BMI: 
In  this  present  study  increased  serum  leptin  level  is  associated  with  
increase  in  BMI66,  waist  hip  ratio  and  waist  height  ratio.  It  is 
similar  to  the  findings  of  previous  studies36,72.  Leptin  concentrations  
were  strongly  correlated  with  various   anthropometric  measures  in  
women  and  men,  both  in  the  univariate  analysis  and  when  age  and  
ethnicity  were  controlled  for.  It  was  revealed  that,  leptin   
concentrations  were  associated   with  both  waist  and  hip  
circumferences,  circumference  ratios  and  with  skin  fold  thicknesses,  
independent  of  BMI79.   
Body  mass  index  and  waist  circumference  were  strongly  positively  
correlated  with  leptin  concentration  in  both  men  and  women43,77.  
Waist   hip  ratio  also  strongly  correlated  with  leptin  concentration42.  
Concentrations  were  higher  in  women  than  in  men,  even  at  the  
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same  body  mass  index  or  waist  circumference.   So  it  was   
suggested   that  blood  leptin  concentration  was  regulated  by  
important  variables  like  physical  activity,  nutritional  factors,  
genotype,  fat  distribution ,  insulin  and  other  hormones71.                   
Technologies  such  as  bioelectric  impedance,  hydrodensitometry and  
dual  energy  X - ray  absorptiometry  ( DEXA)  have  shown  a  strong 
correlation  between  leptin  and  fat  mass,  weight,  percent  body  fat  
and   BMI70. 
Several  studies  also  found  that  leptin  concentrations  were  
significantly  correlated  with  fat  distribution  independent  of  overall  
obesity.  Presence  of  excessive  adipose  tissue  produces  excess  
hormone leptin.  But  selective  resistance  occurs  to  its  weight  
reducing  action73.  So   high  level  of  appetite  inducing  hormone  
leptin  is  seen  in  obesity.  The reason  for  this  is,   may  be  the  
presence  of  abnormal  leptin  protein  and  leptin   receptor  protein . 
This  may  be   because  of  the  mutation  in  ob  gene  resulting  in  
malfunctioning  of  leptin   protein.  This  mutation  causes  synthesis  of  
a  truncated  receptor  lacking  both  the  transmembrane  and  the  
intracellular  domain.  It  blocks  binding  of  leptin  to  the  membrane  
bound  receptor  cell  in  the  hypothalamus  and  led  to  the  hypothesis  
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of  resistance  to  the  action  of  leptin  at  the  level  of  hypothalamus  
causing  increased  appetite  and   decreased  energy  expenditure  despite   
adequate  leptin   production  by  adipocytes73.  
More  recently  it  was  found  that  blood  brain   barrier  transportation  
has  a  threshold  level  for  serum  leptin ( about 25 – 30  ng/ml )  beyond  
which  increase  in  serum  leptin  levels  are  not  translated   into  
proportional  increase  in  cerebrospinal  or  brain  leptin   levels.  
Sexual  dimorphism  in  serum  leptin  levels: 
In  this  present  study  there  is  a  gender  difference  in  serum leptin  
levels.  Females  are  having  high  serum  leptin  levels  when compare  
to  males.  But  the  difference  is  not  statistically  significant.  But  
many   studies  have  found  a  statistically  significant  gender  difference  
in serum  leptin  levels.  Women  have  more  serum  leptin  levels  than 
men62,74-75,77.  According  to  them,  the  possible  reason  for  the  gender  
difference  in  leptin  levels  may  be   the  difference  in  fat  depots  
between  men  and  women.  Men  have  lower  levels  of  overall  
adiposity  but  greater  visceral  adiposity  than  women74.  Females  are  
having  more  subcutaneous  fat  than  males.  Subcutaneous  fat  
produces   more  leptin  mRNA  than  visceral  fat13,77. This  could  
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explain  why  women  have  more  leptin  levels,  as  they  have  more  
subcutaneous  fat  than  visceral  fat.  
So  the  difference  in  body  fat  distribution  and  the  inducing  effects 
of  estrogen,  progesterone  combined  with  the  suppressive  effect  of 
androgens  on  leptin  might  be  the  reason  for  gender  difference  in  
serum  leptin  levels65.  Leptin   regulators   such  as  proopiomelanocortin 
contain  estrogen  and  testosterone  responsive  elements.  
In  one  such  study,  women  of  all  ethnic  groups  had  substantially  
higher  fasting  serum  leptin  concentrations  than  men.  Heightened  
hypothalamic  feedback  loop  in  leptin  adiposity  regulation  in  female  
is    the   mechanism  suggested  by  them.  Samsad  Jahan  and   his  
colleagues did  a  study  in  newborn  babies  to  find  out  the  gender  
difference  in  plasma  leptin  levels.  They  found  a  significant  
difference  in  leptin  levels  between  male  and  female  babies.  So  the  
gender  dimorphism  in  leptin   production  observed  very  early  in  life  
indicates  the  genetic  difference  in  leptin   production78.  
Another  possible  explanation  for  the  sexual  dimorphism  in leptin  
levels  could  be  differences  in  the  hypothalamus  between  women and  
men.  Leptin  exerts  its  effect  by  suppressing  hypothalamic 
neuropeptide  Y  synthesis  thereby  decreasing  food  intake.  There  are  
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gender  differences  in  the  regional  distribution  of  neuropeptide  Y  
mRNA  containing  cells  in  the  hypothalamus.  However  it  is  not  
known  whether  this  structural  gender  difference  in  hypothalamus  is  
associated  with  functional  differences  in  leptin  signalling  and  leptin  
levels74.  
But   studies  related  to  serum  leptin  levels  in  pre  and  post  
menopausal  subjects   suggested  that  estradiol  concentration  is  not  
responsible  for  the  gender  difference  in  serum  leptin  levels70,80.  
It  has  been  also  observed  that  there  is  no  relationship  between  
leptin  concentration  and  age.  Menopausal  status,  age,  Diabetes  and  
body  fat  distribution  do  not  appear  to  modulate  leptin  physiology74. 
Influence  of   plasma  leptin  levels  in  development  of  
cardiovascular complications:  
Circulating  levels  of  leptin  were  found  to  be  significantly  associated  
with  established  cardiovascular  risk  factors  such  as  elevated  blood  
pressure  and  obesity76.  Increased  fasting  plasma  leptin  levels  appear  
to  be  related  to  various  cardiovascular  diseases  including  stroke  and  
Myocardial  infarction7,50,53,72,81.  Leptin  thus  seems  to  play  an  
important  role  in  development  of  complications  of  obesity  and  
hypertension. 
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In  one  of  the   previous  studies,  they   had  analyzed  the  results  from  
clinical  surveys   on  leptin  interaction  with  cardiovascular  diseases  
and  observed  that  the  plasma  leptin  is  higher  in  male  patients  who  
subsequently  develop  first  ever  myocardial   infarction   than  in  
control  subjects.  They  have  concluded  that  leptin  is  a  predictor  of  
myocardial  infarction,  coronary  events  and  stroke  independent  of  
body  mass  index47.  
In  another  study  also,  they  have  concluded  that  plasma  leptin  
strongly  predicts  first -  ever  AMI ( acute  myocardial  infarction )  and  
also  first – ever  haemorrhagic  stroke76 . Thus  serum  leptin  could  be  
considered  as  an  additional  component  of  metabolic  syndrome  and  a  
new  cardiovascular  risk  factor48,77. 
The  following  mechanism  is  proposed  to  the  development  of 
complications:  Leptin  receptors  have  also  been  identified  in  blood 
vessels,  where  they  promote  angiogenesis72.  Previous   reports  have  
shown  that  high  levels  of  leptin  was  associated  with  insulin  
resistance and  increase  in  markers  of  inflammation  including  high  
sensitivity  CRP  levels58,81.   
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Farhan  Jaleel  and  Anila  Jaleel  et  al  observed  a  significant  positive 
correlation  between  leptin  and  lipid  profile  except  HDL  cholesterol  
in their  study12,43.  These  cluster  of  risk  factors  like  insulin  resistance  
and abnormal  lipid  profile  contribute  to  the  development  of  
metabolic  syndrome  thereby  promoting  cardiovascular  complications. 
In  our  study  we  observed  a  strong  positive  correlation between  
serum  leptin  levels  and  blood  pressure  in  association  with BMI,  
waist  hip  ratio,  waist  height  ratio.  So  high  serum  leptin  level  in 
healthy  individuals  would  indicate  future  development  of  
hypertension  whereas  in  hypertensives  it  would  indicate  increased  
risk  of  development  of  complications.  So  it  is  necessary  to  do  an  
estimation of  serum  leptin  level  in  all  hypertensive  patients  and  
persons  who  are  in  at  risk  of  developing  hypertension. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
SUMMARY 
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SUMMARY 
 Serum  leptin  level  is  increased  in  hypertensive  patients  when 
compared  to  normotensive  individuals.  And  also  there  is  
positive correlation  between  serum  leptin  level  and  systolic  
blood  pressure  in  hypertensive  patients.  
 
 Increased  serum  leptin  level  is  associated  with  increase  in  
Body  mass  index,  Waist  hip  ratio  and  Waist  height  ratio. 
 
 As  age advances serum leptin level  also increases  in  
hypertensive patients.  High  serum  leptin  level  is  associated  
with  long  duration  of  hypertension.  
 
 There  is  no  gender  difference  in  serum  leptin  levels  in   
hypertensive  patients. 
 
 
 
 
 
  
 
 
 
CONCLUSION
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                                        CONCLUSION 
In  developed  and  developing  countries,  hypertension  has  been  
identified  as  an  expanding  health  crisis.  It  is  one  of  the  cardinal  
risk  factor  for  cardiovascular  and  cerebrovascular  complications  
thereby  one  of  the  leading  cause  of  disability  and  death  worldwide.  
So  it  has  to  be  detected  at  the  earliest  possible  stage  and  treated   
properly.  
Hypertension  has  a  multifactorial  etiology,  and  there are several   
hypothesis  postulated  regarding  its  pathophysiology.  One  such  recent  
hypothesis  is,  chronic  elevation  in  serum  leptin  level  leading  to  the  
development  of  hypertension. The  mechanism  behind  this  is,  leptin  
causes  wide   spread  activation  of  the  sympathetic  nervous  system,  
sodium  retention  by  kidneys,  activation  of  Renin  Angiotensin  
system,  stimulation  of  reactive  oxygen  species,  impaired  nitric  oxide  
(NO)  production  and  increased  endothelin  1  synthesis  thereby  
resulting  in  elevation  of  blood  pressure.  
Though  the  central  action  of  leptin  is  mainly  appetite suppression  
and  increase  in  energy  expenditure,  high  serum  leptin  levels  are   
seen  in  obese  persons.  Since  leptin  is  synthesised  from  adipose  
tissue,  hyperleptinemia  is  found  in  obesity,  which  is  a  major  
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comorbid  condition  of  hypertension.  In  these  patients,   selective  
resistance  develops  to  the  central  weight  reducing  actions  of  leptin  
whereas  peripheral  actions  like  sympathoexcitatory  actions  of  leptin  
are  preserved.   
There  is  a  strong  positive  correlation  between  serum  leptin  level  
and  high  blood  pressure,  body  mass  index, waist  hip  ratio  and  
Waist  height  ratio  in  this  present  study.   
There  is  also  evidence  that  leptin  has  a  prohypertensive  effect,  that  
is  increased  free  leptin  level  predicts  the  future  development  of 
hypertension.  So  in  high  risk  individuals  like  persons  with  increased  
BMI,  increased  waist  hip  ratio,  increased  waist  height  ratio  and  
healthy  off springs  of  hypertensive  parents,   estimation  of  serum  
leptin  level  may  be  helpful  to  predict  the  risk  of  developing    
hypertension   in  the  future.   
Leptin  seems  to  play  an  important  role  in  development  of  
cardiovascular  complications. Recent  studies  report  that  plasma  leptin  
levels  could  contribute  to  various  cardiovascular  events  including  
stroke  and  myocardial  infarction.  Hypertension  itself  is  a  risk  factor  
for  those  complications  and  leptin  acts  as  an  added  risk  to  that.  
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Hence  leptin  in  hypertension  has  become  a  topic  of  extensive  
ongoing  research  and  this  may  contribute  to  the  emerging  concept  
that  serum  leptin  level  may  serve  as  a  biomarker  for  hypertension  
and  its  complications.  
LIMITATION  OF  THE  PRESENT  STUDY: 
In  this  present  study,  sample  size  is  very  small.  A  large sample  
size  and  longitudinal  study  will  be  of  great  value  to demonstrate  the  
positive  association  between  serum  leptin  level  and blood  pressure  
in  our  population.       
FUTURE  SCOPE  OF  THE  STUDY : 
The  study  can  be  extended  as  a  prospective  study  to  find  out the  
association  between  high  serum  leptin  level  and  incidence  of 
hypertension  in  healthy  individuals. 
Future  studies  should  emphasize  the  association  between  serum  
leptin  levels  and  complications  of  hypertension.  The  possible 
beneficial  role  of  recombinant  leptin  administration  in  the  treatment 
of  obesity  and  prevention  of  metabolic  syndrome  and  cardiovascular 
complications   can  be  found  out. 
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
Dr.G.Malarvizhi,  Post  graduate  student  in  the  department  of  
physiology,  Coimbatore  Medical College  is  studying  ‘Serum  Leptin  
level  and  its  association  with  Blood  Pressure,  Body  Mass  Index, 
Waist  Hip  Ratio and Waist  Height  Ratio’. The  test  procedures  of  the  
measurement  of  height,  weight,  waist  and  hip circumference, 
collection  of   blood  specimen,  recording  of  blood  pressure  with  
sphygmomanometer  were  explained  to  me clearly.  I understand  that  
there   are  no  risks  involved  in  the  above  procedure. 
I  hereby  give  my  consent  to  participate  in  this  study.  The  data 
obtained  herein  may  be  used  for  research  and  publication. 
Name: 
Place: 
Sign : 
                                                         
 
 
 
                                         PROFORMA 
Name: 
Age: 
Sex: 
Occupation: 
Address: 
 
Phone  number: 
Present  history  of  Hypertension: 
H/O  Duration : 
H/O  Drug intake : 
 
H/O  any  complications: 
 Chest  pain  
 Transient  ischemic  attacks 
 Puffiness  of  face 
 Any  visual  problems 
o Photopsia 
o Metamorphosis 
o Black  spots 
o Floaters 
 
History  to  rule  out  Secondary  Hypertension: 
 H/O  Snoring 
 H/O  Excessive  day  time  sleepiness 
 H/O  Apnoea 
 H/O  Nocturnal  arousal 
 H/O  any  substance  abuse    
                               (Amphetamine/Cocaine) 
 H/O  Drug  intake: 
    1.Decongestants 
    2.Oral  contraceptives 
    3.NSAIDS 
    4.Exogenous  thyroid  
    5.Hormone  replacement  therapy 
 H/O  Weight  gain 
 H/O  Weight  loss 
 H/O  Claudication 
 H/O  Puffiness  of  face  in  early  morning 
 H/O  Decreased  urine  output 
 H/O  Bladder  incontinence 
 H/O  Postural  Hypotension 
 H/O  Light  headedness     
 
Past  history: 
   H/O  Diabetes  Mellitus 
  H/O  Any  renal  diseases 
   H/O  Any  liver  diseases 
   H/O  Thyroid  disorder 
 
Family  history:   
H/O  Systemic  hypertension,   Diabetes  mellitus 
Personal  history:  
  H/O  Smoking   and  H/O  Alcohol  intake. 
 
GENERAL  EXAMINATION: 
                 Built: 
                 Height: 
                 Weight:                           BMI: 
                 Waist  circumference :                               Hip  Circumference : 
                 WHR :                                                        WHtR : 
                  
                 Peri  orbital  puffiness,    thick  dry  skin  
                 Pallor,   Icterus,   Clubbing,   Cyanosis 
                 Lymphadenopathy,    Pedal  edema. 
 
Vital signs : 
                PR:                                                       RR: 
 
                BP:                                                              Temp: 
 
 
 
 
 SYSTEMIC EXAMINATION 
                 
INSPECTION 
 Shape   of  the  chest 
 Apical  Impulse 
 JVP 
 Movement  of  the  chest 
 Visible   Pulsations 
 Engorged  veins  in  the  neck , engorged  and  dilated  superficial 
veins  over  the  precardium. 
 
 
PALPATION 
 Position  of  trachea  
 Apex  Beat 
 Parasternal  Heave 
 Thrill 
 
 
AUSCULTATION:   
 CVS:  
Heart sounds : 
  Murmur : 
 
RS: 
Breath  sounds : 
  Added  sounds : 
 
P/A:  
Soft : 
  Tenderness : 
  Distension:  
 
CNS : 
          Focal neurological deficit : 
 
                                                         
                                    INVESTIGATIONS  
 Fasting  serum  leptin  level : 
 
 
 
 
  
        
         MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
MASTER CHART 
 
  
Study group : H
ypertensive patients; M
ales 
SBP: Systolic blood pressure;  D
BP: D
iastolic blood pressure;   BM
I: Body m
ass index;    W
H
R
: W
aist hip ratio;      W
H
tR
: W
aist height ratio 
 
                                                                      
S.N
o 
Sex 
age 
leptin 
SB
P 
D
B
P 
B
M
I 
hight 
w
eight 
w
aist 
hip 
W
H
R
 
W
H
tR
 
D
uration  
1. 
 
M
A
LE 
48 
6.2 
160 
90 
27 
172 
80 
89 
95 
0.96 
0.51 
7 
2. 
 
M
A
LE 
36 
5.5 
140 
100 
26.95 
168 
76 
94 
98 
0.95 
0.55 
2 
3. 
 
M
A
LE 
49 
7.3 
186 
110 
29.53 
154 
70 
99 
106 
0.93 
0.64 
6 
4. 
 
M
A
LE 
68 
13.4 
210 
110 
32.82 
162 
86 
102 
106 
0.96 
0.62 
10 
5. 
 
M
A
LE 
59 
14.9 
180 
96 
29.49 
167 
82 
101 
105 
0.96 
0.6 
12 
6. 
 
M
A
LE 
45 
6.7 
148 
92 
28.47 
174 
86 
96 
100 
0.96 
0.55 
5 
7. 
 
M
A
LE 
50 
3.6 
140 
90 
28.48 
178 
90 
96 
100 
0.96 
0.53 
7 
8. 
 
M
A
LE 
43 
9.4 
170 
86 
30.17 
169 
86 
103 
108 
0.95 
0.6 
3 
9. 
 
M
A
LE 
49 
4.8 
130 
76 
29.77 
176 
92 
101 
106 
0.95 
0.57 
7 
10. 
 
M
A
LE 
48 
10.2 
160 
100 
29.41 
175 
90 
96 
100.5 
0.95 
0.54 
8 
11. 
 
M
A
LE 
70 
8.4 
166 
110 
32.83 
163 
87 
106 
108 
0.98 
0.65 
20 
12. 
 
M
A
LE 
50 
6.6 
158 
100 
32.2 
172 
95 
104 
106 
0.99 
0.6 
5 
13. 
 
M
A
LE 
55 
12.5 
180 
90 
32.08 
164 
86 
99 
103 
0.95 
0.6 
10 
14. 
 
M
A
LE 
48 
5.3 
132 
76 
29.12 
176 
90 
99.5 
104 
0.95 
0.56 
7 
15. 
 
M
A
LE 
42 
8.6 
160 
80 
31.16 
152 
72 
102 
104 
0.98 
0.67 
4 
16. 
 
M
A
LE 
51 
11.6 
160 
100 
31.03 
179 
90 
99 
105 
0.94 
0.55 
8 
17. 
 
M
A
LE 
55 
10.3 
180 
110 
30.88 
161 
80 
98 
102 
0.94 
0.6 
9 
18. 
 
M
A
LE 
57 
6.4 
148 
92 
24.26 
165 
66 
88 
93 
0.94 
0.53 
10 
19. 
 
M
A
LE 
53 
5.5 
168 
96 
28.36 
168 
80 
98 
102 
0.95 
0.58 
5 
20. 
 
M
A
LE 
53 
5.5 
120 
92 
27.84 
154 
66 
99 
104 
0.94 
0.64 
3 
21. 
 
M
A
LE 
65 
7.8 
140 
90 
27.18 
176 
84 
94 
98 
0.95 
0.53 
10 
22. 
 
M
A
LE 
59 
9.7 
162 
96 
28.1 
175 
86 
92 
97 
0.94 
0.52 
8 
23. 
 
M
A
LE 
55 
11.8 
210 
110 
28.08 
171 
82 
95 
100 
0.95 
0.55 
10 
24. 
 
M
A
LE 
67 
12.4 
184 
100 
31.22 
162 
84 
101 
104 
0.97 
0.62 
12 
25. 
 
M
A
LE 
43 
7.4 
190 
90 
32.04 
153 
74 
100.5 
103 
0.97 
0.65 
4 
26. 
 
M
A
LE 
57 
7.6 
130 
76 
26.08 
186 
90 
92 
97 
0.94 
0.49 
7 
Study group : H
ypertensive patients; Fem
ales 
              
             
SBP: Systolic blood pressure;  D
BP: D
iastolic blood pressure;   BM
I: Body m
ass index;    W
H
R
: W
aist hip ratio;      W
H
tR
: W
aist height ratio 
 
   
S.N
o 
Sex 
age 
leptin 
SB
P 
D
B
P 
B
M
I 
hight 
w
eight 
w
aist 
hip 
W
H
R
 
W
H
tR
 
duration 
1. 
 
FEM
A
LE 
69 
6.2 
160 
100 
30.18 
163 
80 
90 
102 
0.88 
0.55 
12 
2. 
 
FEM
A
LE 
72 
8.4 
176 
102 
28.12 
152 
65 
87 
98 
0.86 
0.57 
15 
3. 
 
FEM
A
LE 
48 
5.2 
140 
100 
26.47 
165 
72 
92 
100 
0.92 
0.55 
7 
4. 
 
FEM
A
LE 
46 
9.9 
180 
110 
31.96 
148 
70 
102 
110 
0.92 
0.68 
6 
5. 
 
FEM
A
LE 
59 
13.4 
130 
90 
27.19 
151 
62 
87 
98 
0.88 
0.57 
10 
6. 
 
FEM
A
LE 
55 
8.8 
140 
90 
25.3 
158 
63 
88 
99 
0.88 
0.55 
8 
7. 
 
FEM
A
LE 
65 
6.7 
160 
110 
31.7 
157 
78 
97 
106 
0.91 
0.61 
5 
8. 
 
FEM
A
LE 
59 
8.9 
210 
110 
37.25 
143 
76 
102 
110 
0.92 
0.71 
8 
9. 
 
FEM
A
LE 
56 
7.9 
130 
100 
30.53 
162 
80 
95 
102 
0.93 
0.58 
6 
10. 
 
FEM
A
LE 
60 
6.7 
140 
98 
29.68 
161 
76 
90 
102 
0.88 
0.55 
10 
11. 
 
FEM
A
LE 
60 
6.8 
180 
100 
32.93 
158 
82 
101 
108 
0.93 
0.63 
20 
12. 
 
FEM
A
LE 
41 
5.1 
140 
90 
26.58 
159 
67 
85 
96 
0.88 
0.53 
4 
13. 
 
FEM
A
LE 
56 
4.1 
140 
100 
25.66 
163 
68 
86 
98 
0.87 
0.52 
7 
14. 
 
FEM
A
LE 
60 
9.8 
140 
90 
28.12 
160 
72 
84 
96 
0.87 
0.52 
10 
15. 
 
FEM
A
LE 
57 
12.1 
160 
110 
32.05 
153 
75 
102 
110 
0.92 
0.66 
12 
16. 
 
FEM
A
LE 
58 
7.7 
140 
90 
24.05 
143 
50 
82 
96 
0.85 
0.57 
10 
17. 
 
FEM
A
LE 
55 
5.7 
160 
100 
27.08 
155 
65 
90 
98 
0.89 
0.58 
6 
18. 
 
FEM
A
LE 
45 
6.2 
120 
80 
28.91 
158 
72 
93 
102 
0.9 
0.58 
5 
19. 
 
FEM
A
LE 
55 
8.4 
140 
100 
27.92 
149 
62 
87 
99 
0.88 
0.58 
8 
20. 
 
FEM
A
LE 
65 
9.6 
152 
96 
26.96 
143 
55 
89 
98 
0.9 
0.62 
12 
21. 
 
FEM
A
LE 
53 
5.5 
140 
90 
25.98 
170 
68 
85 
95 
0.89 
0.5 
2 
22. 
 
FEM
A
LE 
43 
8.7 
200 
90 
29.19 
146 
62 
91 
102 
0.89 
0.62 
2 
  
C
ontrol  group : N
orm
otensive m
ales 
              
             SBP: Systolic blood pressure;  D
BP: D
iastolic blood pressure;   BM
I: Body m
ass index;    W
H
R
: W
aist hip ratio;      W
H
tR
: W
aist height ratio 
 
  
S.N
o 
Sex 
age 
leptin 
SB
P 
D
B
P 
B
M
I 
hight 
w
eight 
w
aist 
hip 
W
H
R
 
W
H
tR
 
1. 
 
M
A
LE 
35 
2.2 
110 
70 
26 
171 
76 
92 
100 
0.92 
0.53 
2. 
 
M
A
LE 
42 
0.5 
130 
78 
24.07 
180 
78 
89 
98 
0.9 
0.49 
3. 
 
M
A
LE 
45 
1.3 
120 
80 
24.26 
180 
84 
94 
101 
0.93 
0.52 
4. 
 
M
A
LE 
52 
1.4 
118 
60 
23.16 
161 
60 
90 
99 
0.9 
0.55 
5. 
 
M
A
LE 
68 
3.7 
120 
80 
25.88 
176 
80 
91 
97 
0.93 
0.51 
6. 
 
M
A
LE 
56 
1.4 
110 
76 
23.66 
184 
80 
92 
100 
0.92 
0.5 
7. 
 
M
A
LE 
72 
2.7 
112 
80 
24.05 
178 
76 
88 
96 
0.91 
0.49 
8. 
 
M
A
LE 
61 
0.5 
120 
70 
24.26 
184 
82 
92 
98 
0.93 
0.5 
9. 
 
M
A
LE 
55 
0.4 
110 
70 
22 
186 
60 
86 
98 
0.87 
0.46 
10. 
 
M
A
LE 
54 
0.6 
120 
80 
23.05 
172 
68 
90 
101 
0.89 
0.52 
11. 
 
M
A
LE 
66 
1.4 
100 
60 
24.82 
168 
70 
91 
98 
0.92 
0.54 
12. 
 
M
A
LE 
44 
1.8 
110 
80 
25.55 
177 
80 
98 
104 
0.94 
0.55 
13. 
 
M
A
LE 
48 
1 
120 
70 
25.98 
182 
86 
99 
106 
0.93 
0.54 
14. 
 
M
A
LE 
54 
0.6 
120 
80 
23.52 
170 
68 
91 
100 
0.91 
0.53 
15. 
 
M
A
LE 
43 
0.4 
110 
70 
24.55 
183 
82 
92 
98 
0.93 
0.5 
16. 
 
M
A
LE 
39 
0.8 
116 
76 
25.89 
167 
72 
96 
102 
0.94 
0.57 
17. 
 
M
A
LE 
58 
0.6 
110 
80 
25.16 
174 
76 
98 
104 
0.94 
0.56 
18. 
 
M
A
LE 
57 
2.2 
100 
80 
22.87 
175 
70 
88 
98 
0.89 
0.5 
19. 
 
M
A
LE 
45 
2.5 
100 
70 
24.07 
180 
78 
91 
101 
0.9 
0.5 
20. 
 
M
A
LE 
43 
1.2 
110 
70 
26.75 
173 
80 
100 
104 
0.96 
0.57 
21. 
 
M
A
LE 
48 
0.3 
120 
82 
26.08 
186 
90 
99 
103 
0.96 
0.53 
22. 
 
M
A
LE 
46 
2.6 
90 
60 
25.88 
176 
80 
96 
102 
0.94 
0.54 
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                  SBP: Systolic blood pressure;  D
BP: D
iastolic blood pressure;   BM
I: Body m
ass index;    W
H
R
: W
aist hip ratio;      W
H
tR
: W
aist height ratio 
 
 
S.N
o 
Sex 
age 
leptin 
SB
P 
D
B
P 
B
M
I 
hight 
w
eight 
w
aist 
hip 
W
H
R
 
W
H
tR
 
1. 
 
FEM
A
LE 
43 
0.9 
122 
78 
24.07 
146 
52 
82 
92 
0.89 
0.56 
2. 
 
FEM
A
LE 
67 
1.6 
120 
80 
23.8 
152 
55 
78 
90 
0.86 
0.51 
3. 
 
FEM
A
LE 
45 
1.9 
110 
68 
25.48 
161 
66 
86 
96 
0.89 
0.53 
4. 
 
FEM
A
LE 
62 
1.9 
100 
60 
24.52 
163 
65 
76 
88 
0.86 
0.46 
5. 
 
FEM
A
LE 
65 
1.7 
104 
78 
20.88 
158 
52 
74 
84 
0.88 
0.46 
6. 
 
FEM
A
LE 
56 
1.4 
110 
70 
25.45 
166 
70 
88 
92 
0.95 
0.53 
7. 
 
FEM
A
LE 
38 
2.1 
120 
80 
25.51 
156 
62 
81 
94 
0.86 
0.51 
8. 
 
FEM
A
LE 
48 
3.7 
130 
76 
25.6 
157 
63 
79 
91 
0.88 
0.5 
9. 
 
FEM
A
LE 
40 
1.2 
120 
78 
25.97 
152 
60 
84 
96 
0.87 
0.55 
10. 
 
FEM
A
LE 
42 
0.6 
112 
76 
25.22 
149 
56 
87 
99 
0.87 
0.58 
11. 
 
FEM
A
LE 
47 
1.5 
120 
70 
27.16 
163 
72 
92 
102 
0.9 
0.56 
12. 
 
FEM
A
LE 
56 
3 
110 
68 
26.56 
160 
68 
89 
97 
0.92 
0.55 
13. 
 
FEM
A
LE 
66 
0.3 
110 
70 
24.09 
158 
60 
80 
89 
0.89 
0.5 
14. 
 
FEM
A
LE 
43 
2.5 
120 
82 
27.08 
155 
65 
90 
98 
0.91 
0.58 
15. 
 
FEM
A
LE 
48 
3.2 
116 
86 
27.57 
165 
75 
90 
101 
0.89 
0.54 
16. 
 
FEM
A
LE 
55 
3.6 
120 
78 
26.5 
158 
66 
86 
98 
0.87 
0.54 
17. 
 
FEM
A
LE 
62 
2.7 
110 
60 
22.9 
162 
60 
80 
90 
0.88 
0.49 
18. 
 
FEM
A
LE 
46 
3.6 
110 
70 
25.37 
164 
68 
84 
96 
0.87 
0.51 
19. 
 
FEM
A
LE 
43 
3.2 
120 
80 
26.5 
158 
66 
96 
104 
0.92 
0.6 
20. 
 
FEM
A
LE 
51 
2.3 
100 
70 
26.58 
154 
63 
90 
98 
0.91 
0.58 
